Humanized antibody potently neutralizes all SARS-CoV-2 variants by a novel mechanism

Sai Luo[1,2*†], Jun Zhang[3,4†], Alex J.B. Kreutzberger[5,6†], Amanda Eaton[7,8], Robert J. Edwards[7,8], Changbin Jing[1,2], Hai-Qiang Dai[1,2], Gregory D. Sempowski[7,8], Kenneth Cronin[7,8], Robert Parks[7,8], Adam Yongxin Ye[1,2], Katayoun Mansouri[7,8], Maggie Barr[7,8], Novalia Pishesha[9], Aimee Chapdelaine Williams[1,2], Lucas Vieira Francisco[1,2], Anand Saminathan[5,6], Hanqin Peng[3,4], Himanshu Batra[1,2], Lorenza Bellusci[10], Surender Khurana[10], S. Munir Alam[7,8], David C. Montefiori[7,11], Kevin O. Saunders[7,11,12], Ming Tian[1,2], Hidde Ploegh[9], Tom Kirchhausen[5,6*], Bing Chen[3,4*], Barton F. Haynes[7,8,12*], and Frederick W. Alt[1,2*]

[1]Howard Hughes Medical Institute, Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
[2]Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
[3]Division of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
[4]Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
[5]Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA;
[6]Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
[7]Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
[8]Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.
[9]Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
[10]Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, USA
[11]Department of Surgery, Duke University, Durham, NC 27710, USA.
[12]Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.

[†]These authors contributed equally to this work.

*Correspondence: sai.luo@childrens.harvard.edu (S.L.), kirchhau@crystal.harvard.edu (T.K.), bchen@crystal.harvard.edu (B.C.), barton.haynes@duke.edu (B.F.H.), alt@enders.tch.harvard.edu (F.W.A.)

40   **Abstract**

41   SARS-CoV-2 Omicron variants have generated a world-wide health crisis due to

42   resistance to most approved SARS-CoV-2 neutralizing antibodies and evasion of antibodies

43   induced by vaccination. Here, we describe the SARS-CoV-2 neutralizing SP1-77 antibody that

44   was generated from a humanized mouse model with a single human V_H1-2 and Vκ1-33-

45   associated with immensely diverse complementarity-determining-region-3 (CDR3) sequences.

46   SP1-77 potently and broadly neutralizes SARS-CoV-2 variants of concern and binds the SARS-

47   CoV-2 spike protein receptor-binding-domain (RBD) via a novel-CDR3-based mode. SP1-77

48   does not block RBD-binding to the ACE2-receptor or endocytosis step of viral entry, but rather

49   blocks membrane fusion. Our findings provide the first mechanistic insight into how a non-

50   ACE2 blocking antibody potently neutralizes SARS-CoV-2, which may inform strategies for

51   designing vaccines that robustly neutralize current and future SARS-CoV-2 variants.

MAIN TEXT

52

53   The SARS-CoV-2 Omicron variant of concern has spread worldwide and remains the

54   cause of a public health crisis. This variant has an unprecedented number of mutations in its

55   spike protein, is resistant to most prior SARS-CoV-2-neutralizing antibodies, and evades

56   antibodies induced by vaccinations (*1-6*). The Omicron BA.2 sub-variant dominates cases in

57   South Africa, China, and other countries and has exacerbated the impact of the Omicron wave

58   world-wide. Moreover, new Omicron sub-variants continue to emerge, including BA2.12.1,

59   BA.4 and BA.5 (*7-9*). The few published human monoclonal antibodies that neutralize omicron

60   BA.1 and BA.2 came from B cells of human patients previously infected by SARS-CoV-2 (*1-6*).

61   To manage Omicron sub-variants and prepare for potential future SARS-CoV-2 variants of

62   concern (VOCs), new human or humanized antibodies that robustly neutralize all SARS-CoV-2

63   VOCs are needed. In addition, a characterization of their mechanism of action will be essential.

64   Binding of the SARS-CoV-2 spike protein to its obligate angiotensin-converting enzyme

65   2 (ACE2) receptor on the target cell surface initiates infection (*10*). The spike protein is made up

66   of non-covalently linked S1 and S2 subunits (*11*). The receptor-binding-domain (RBD) for

67   ACE2 is located in the S1 subunit, while the S2 subunit anchors the spike protein in the viral

68   membrane. The S2 subunit also contains other sequences that mediate viral/host cell membrane

69   fusion for viral entry. The RBD can adopt two distinct conformations: "down" and "up"; the

70   "down" state is shielded from ACE2 binding, while the "up" state is ACE2-accessible (*12*).

71   Engagement of ACE2 by an "up" RBD exposes the S2' cleavage site on the S2 subunit to either

72   the serine 2 (TMPRSS2) transmembrane protease at the infected cell surface, or to cathepsin L in

73   the endosomal compartment following endocytosis of the ACE2/SARS-CoV-2 complex (*13*).

74   Cleavage of the S2 subunit by these proteases leads to dissociation of the S1 subunit, which

75   exposes the fusion peptide on the S2 subunit and ultimately leads to fusion pore formation, viral-

76   host membrane fusion, and viral entry into the infected cell (*14*).

77   Therapeutic SARS-CoV-2 neutralizing antibodies (nAbs) that block virus entry into host

78   cells have demonstrated substantial efficacy for treating COVID-19 infections. The majority of

79   such nAbs target the SARS-CoV-2 RBD and inhibit viral entry by binding to the ACE2 receptor

80   binding motif (RBM), thereby, directly impeding its binding to the ACE2 receptor(*1*). Other

3

81   nAbs bind outside of the RBM, but sterically inhibit ACE2 binding (*15*). A few reported SARS-

82   CoV-2 nAbs bind outside of the RBM and do not inhibit ACE2 binding, but can still potently

83   neutralize SARS-CoV-2 VOCs (*1, 16, 17*). How the latter class of nAbs neutralizes SARS-CoV-

84   2 is not known.

85   A vast portion of the primary antibody repertoire diversity lies in the antigen-contact

86   CDR3-encoding variable region sequences generated *de novo* by non-templated V(D)J junctional

87   modifications during V(D)J recombination (*18*). Indeed, the number of CDR3 sequences that can

88   be generated through junctional diversification exceeds the number of B cells in mammalian

89   immune systems by many orders of magnitude (*19*). Thus, the relative size of the primary BCR

90   repertoire in humans and mice is determined by the number of primary B cells in their immune

91   system (*20*). Immunoglobin (Ig) gene-humanized mice capable of rearranging the full

92   complement of human *Igh* and *IgL* variable region gene segments have yielded many therapeutic

93   monoclonal antibodies (mAbs), including mAbs that neutralize several SARS-CoV-2 VOCs

94   (*15*). However, these mouse models have not yet been reported to yield Omicron-neutralizing

95   mAbs. There could be many possible explanations for the lack of isolation of mAbs that more

96   broadly neutralize SARS-CoV-2 VOCs from Immunoglobin (Ig) gene-humanized mice. One of

97   these possibilities is that mice express only a tiny fraction of the CDR3-diversity present in

98   human primary BCR repertoire, as a mouse has 1000-fold fewer B cells than a human. Early

99   experiments indicated that BCR repertoires generated from rearrangement of a single V_H and $V\kappa$

100   could make potent responses to diverse antigens due to immense CDR3 diversification (*21*).

101   Building from this observation, we now report that a mouse model that generates more human-

102   like CDR3 diversity in association with rearrangement of a single human V_H and $V\kappa$ can indeed

103   be used to elicit novel SARS-CoV-2 nAbs.

104

RESULTS

Single human V_H- and $V\kappa$-rearranging mouse model for human antibody discovery

107   For these studies, we generated the "V_H1-2/$V\kappa$1-33-rearranging mouse model" that

108   generates primary BCR repertoires via exclusive rearrangement of a single human V_H1-2 and

109   predominant rearrangement of human $V\kappa$1-33 with the primary humanized BCR repertoire

110   diversification based on immense CDR3 diversification (Fig.1A). In this regard, V_H1-2 is

111   frequently represented in SARS-CoV-2 nAbs derived from human patients, but has not

112   contributed to antibodies that broadly neutralize the different VOCs (*22*). For the *Igh* locus in

113   this model, the proximal mouse V_H5-2 was replaced with human V_H1-2, which linked human

114   V_H1-2 to the mouse V_H5-2 downstream CTCF-binding element (CBE) (*23, 24*). All functional

115   mouse V_Hs were deleted from this allele, and robust V_H1-2 rearrangement, mediated by the

116   linked CBE, was enforced through deletion of IGCR1 element in the V_H to D interval (*23-25*)

117   (Fig.1A and fig. S1A). For the *Igκ* locus in this model, the proximal mouse Vκ3-2 that

118   expressed in 2.7% of splenic B cells was replaced with human Vκ1-33, which resulted in

119   expression in 2.2% of splenic B cells (Fig.1, A and B; fig. S1, B and C; table S1). Then, the

120   IGCR1-related Cer/Sis element in the Vκ-Jκ interval was deleted to substantially increase Vκ1-

121   33 utilization to 11% (*26*) (Fig.1, A and B; fig. S1, D and E; table S1). We retained the mouse

122   J_Hs and Jκs in this model as their framework sequences outside of CDR3 are largely conserved

123   between mouse and human (fig. S1F). We also retained the mouse Ds, as mouse Ds are highly

124   related to a subset of human Ds and, in any case, contribution of D segments to CDR3 are often

125   unassignable due to extensive non-templated junctional diversification.

126   In the resulting V_H1-2/Vκ1-33-rearranging mouse model, human V_H1-2 and Vκ1-33

127   contribute to the BCRs expressed by 100% and 11%, respectively, of splenic B cells (Fig. 1B,

128   fig. S2A and table S1). Splenic B and T cell populations in this mouse model were similar in

129   numbers and characteristics to those of wild-type as assessed by cytofluorimetry (fig. S2B).

130   Moreover, analysis of CDR3s in primary BCR repertoires of these mice revealed an immensely

131   diverse V_H1-2-based CDR3 repertoire, as well as a diverse Vκ1-33 repertoire (Fig. 1, C and D).

132   Following immunization, we predicted that the massive CDR3 diversity would contribute to

133   selection into germinal centers of B cells with human V_H1-2- and Vκ1-33-based BCRs, where

134   somatic hypermutations could further diversify variable region exons and contribute to affinity

135   maturation.

136

137   **Identification of novel SARS-CoV-2 neutralizing antibodies**

138   We immunized the human V_H1-2/Vκ1-33-rearranging model with recombinant stabilized

139 soluble SARS-CoV-2 Wuhan-1 spike trimer, or with an RBD monomer fused to a nanobody

140 ("VHH7-RBD") that targets MHC II-complex antigens (27) to potentially increase

141 immunogenicity--given the poor immunogenicity of RBD monomer (28) (Fig. 2A).

142 Immunizations were done twice, four weeks apart, with each immunogen plus poly I:C adjuvant

143 (Fig. 2A). All mice developed strong antibody responses to the SARS-CoV-2 spike or RBD

144 immunogens, as demonstrated by serum IgG titers at 2 weeks and 6 weeks post immunization

145 (fig. S3A). At 3 weeks after the second immunization, 96 antigen-specific IgG[+] B cells were

146 fluorescence-activated single-cell sorted from each mouse and their IgH (HC) and IgL (LC)

147 variable region exons were sequenced (fig. S3B). These experiments identified 9 separate spike-

148 specific B cell lineages, each of which expressed BCRs with unique sets of V_H1-2 and Vκ1-33-

149 associated CDR3s (Fig. 2B). In each CDR3-based lineage, individual members had unique

150 patterns of somatic hypermutations (table. S2). The V_H1-2- based HC CDR3s of these lineages

151 were also unique compared to CDR3s of previously reported V_H1-2-based anti-SARS-CoV-2

152 antibodies. To assess binding properties, we expressed one mAb from each lineage with human

153 IgG1or IgG4 and human Igκ constant regions. ELISAs showed that all bind to the SARS-CoV-2

154 spike protein and 6 bind to the RBD, with one of the latter, termed SP1-77, derived from spike

155 protein immunization (fig. S3C).

156   SARS-CoV-2 pseudovirus neutralization assays revealed that 3 of the RBD-binding

157 mAbs potently neutralized the SARS-CoV-2 G614 virus including VHH7-5-82 (IC_{50}: 38ng/ml),

158 VHH7-7-53 (IC_{50}: 68ng/ml), and SP1-77 (IC_{50}: 20ng/ml) (Fig. 2C and fig. S4A). VHH7-5-82

159 also potently neutralized the Alpha (IC_{50}: 20ng/ml) and Iota (IC_{50}: 43ng/ml) VOCs (Fig. 2C and

160 fig. S4A). VHH7-7-53 also potently neutralized Alpha (IC_{50}: 43ng/ml), Epsilon (IC_{50}: 62ng/ml),

161 Iota (IC_{50}: 43ng/ml) and Delta (IC_{50}: 96 ng/ml) VOCs (Fig. 2C and fig. S4A). Notably, SP1-77

162 potently neutralized all currently known SARS-CoV-2 variants, including robust neutralization

163 of the recently emerging Omicron sub-variants, BA.1 (IC_{50}: 6.5 ng/ml), BA.2 (IC_{50}: 33 ng/ml),

164 BA.3 (IC_{50}: 7 ng/ml), BA.4/BA.5 (IC_{50}: 16 ng/ml) and BA.2.12.1 (IC_{50}: 8 ng/ml) (Fig. 2C and

165 fig. S4A). The IC_{80} neutralization values of SP1-77 against these variants were equally

166 compelling (fig. S4B). Similar neutralization profiles for SP1-77 were found with an

167   independent pseudovirus neutralization assay (fig. S4C). Robust neutralization of variants by

168   SP1-77 also was seen in a plaque reduction neutralization test (PRNT) on live SARS-CoV-2

169   virus, with IC_{50} values ranging from 0.8 to 9.6 ng/ml (Fig. 2D). We also generated an SP1-77-

170   derived antibody in which J_H and Jκ framework sequences outside of CDR3 were fully

171   humanized and found that it retained similar robust neutralization activities against G614, Delta,

172   Omicron sub-variants as SP1-77 (fig. S4D). Finally, we expressed the other four antibodies from

173   the SP1 clonal lineage, each of which has unique pattern of somatic hypermutations compared to

174   SP1-77. All have similar broad and potent neutralization activities (fig. S4D).

175   Surface plasmon resonance (SPR) confirmed interactions of the Fabs of the 3 RBD-

176   binding nAbs with G614 S-2P SARS-CoV-2 spike protein (fig. S5A). Thus, we imaged Spike-

177   Fab complexes using negative-stain electron microscopy (NSEM) to elucidate binding

178   characteristics (fig. S5, B to D). Three-dimensional NSEM reconstructions indicated that VHH7-

179   5-82, VHH7-7-53, and SP1-77 all bind to both up and down RBDs (fig. S5, B to E). However,

180   these reconstructions further indicated that these 3 antibodies have distinct binding footprints.

181   Thus, views of the RBD from the top, front, left, right and back showed that: VHH7-5-82 binds

182   the top and right faces of RBD, overlapping with the RBM (fig. S6A); VHH7-7-53 binds the top

183   face of the RBD, near the front, overlapping more widely with the RBM (fig. S6B); and SP1-77

184   binds the back and right faces, completely outside of the RBM (fig. S6C). Indeed, a surface

185   plasmon resonance competition assay showed that SP1-77 does not compete with ACE2 for

186   binding to the RBD or spike trimer (fig. S6D).

187

188   **cryo-EM structure of G614 S trimer in complex with the SP1-77 Fab**

189   As SP1-77 neutralizes SARS-CoV-2 with remarkable potency and breadth, we

190   determined cryo-EM structures of the full-length G614 S trimer in complex with the SP1-77

191   Fab (*29*) (fig. S7). 3D classification revealed two distinct conformations, including a three-

192   RBD-down conformation and a one-RBD-up conformation, that both bound to three Fabs per

193   S trimer (Fig. 3A) -- consistent with negative stain EM results (fig. S5D). These structures

194   were refined to 2.7Å and 2.9Å resolution, respectively (fig. S7 to S9 and table S3). To

195   improve resolution near the RBD/SP1-77 interface, we performed local refinement, leading to

196   a 3.2 Å map that covers the Fab-RBD interface from the S trimer in the three-RBD-down

197   conformation.   From the S trimer in the one-RBD-up conformation, we obtained maps for the

198   Fab-RBD interfaces in the down conformation and in the up conformation at 3.3 Å and 4.8Å

199   resolution, respectively (fig. S7 to S9).   These structures confirmed that the SP1-77 epitope

200   sits on the opposite side of RBD from the ACE2 binding site (Fig. 3, B and C*)*, consistent

201   with the negative stain EM data and our surface plasmon resonance competition data showing

202   that SP1-77 does not impact ACE2 binding.

203   SP1-77 mainly makes direct contacts with the RBD, but also touches the N-terminal

204   domain (NTD) from a neighboring protomer (Fig. 3B). The interaction buries an 939 $Å^2$

205   surface area on the antibody and an 936 $Å^2$ area from the spike protein.   The HC and LC of

206   SP1-77 contribute to 83% and 17% of the binding surface area, respectively.   In particular,

207   part of the 17-residue HC CDR3 wedges into a short groove formed by two segments in the

208   RBD encompassing residues 343-346 and 441-444, respectively, while the tip of the 343-346

209   segment (mainly Thr345 and Arg346) projects into a ring-like structure formed by the HC

210   CDR3 (Fig. 3B). The intertwined contacts between the HC CDR3 and the RBD account for

211   78% of the binding surface area contributed by the HC. There appears to be an extensive

212   hydrogen bond network between Asn343, Thr345, Arg346, Asn440, Leu441 from the RBD

213   and Val97, Leu98, Tyr99, Gly100, Arg100A, Ser100B from the HC CDR3.   Notably, there is

214   also a salt bridge between Arg346 of the RBD and Asp95 of the HC CDR3. Tyr99 of the HC

215   CDR3 also packs against the fucose residue from the fucosylated Asn-343 glycan (*30*),

216   probably forming a CH-π interaction, which buries a surface area of ~150 $Å^2$ (Fig. 3B). In

217   addition, there are a contacts between the 441-444 segment (Lys444 and Val445) and Tyr32

218   of the LC CDR1 and Asp92 of the LC CDR3 (Fig. 3B). Finally, the SP1-77 HC CDR2 and

219   FW3 makes additional contacts with the Asn122 and Asn165 glycans on the NTD, probably

220   by forming hydrogen bonds or water-mediated hydrogen bonds (Fig. 3B). Overall, the Cryo-

221   EM structure revealed that, compared to other SARS-CoV-2 nAbs, SP1-77 binds a novel RBD

222   epitope outside of the ACE2 binding motif via an interaction substantially mediated by the HC

223   CDR3.

224   When the SP1-77 footprint is projected onto modeled RBDs from different SARS-

225 CoV-2 variants (fig. S10, A and B), it is evident that most mutations are located outside of the

226 SP1-77 binding site, except for the Arg346Lys in the Mu and Omicron-BA.1.1 variants (*31, 32*),

227 and the Gly339Asp and Asn440Lys in all current Omicron sub-variants (*9, 33*). The modeled

228 interfaces of SP1-77 bound to the Mu and Omicron RBDs, based on the SP1-77/G614 S

229 complex, indicate that the conservative Arg346Lys mutation would preserve the interaction with

230 HC CDR3 and not have much impact on binding. Likewise, the Gly339Asp and Asn440Lys

231 mutations are at the edge of the SP1-77 epitope with their side chains pointing away from the

232 binding interface, explaining why Omicron variants are sensitive to SP1-77 neutralization (fig.

233 S10C). While mutations near the Asn343-glycan in Omicron reconfigure the orientation such

234 that the carbohydrate projects away from the protein surface (*34*), such mutations have minimal

235 impact on binding and neutralization activity of SP1-77 (fig. S10C). Finally, we also compared

236 the SP1-77 footprint with the new mutations on the recently emerging Omicron sub-variants,

237 BA.4, BA.5, BA.2.12 and BA.2.12.1. The R357K in BA.2.12 and F486V in BA.4/BA.5 are far

238 from the SP1-77 footprint (fig. S10, A and B); while the L452Q mutation in BA.2.12.1 and

239 L452R mutation in BA.4/BA.5 are close to but do not overlap with SP1-77 footprint. Thus,

240 these structure studies reveal why SP1-77 potently and broadly neutralizes SARS-CoV-2

241 variants, including those that most recently emerged.

242

243 **SP1-77 has a novel neutralization mechanism**

244   To address the SP1-77 neutralization mechanism, we applied a lattice light sheet

245 microscopy (LLSM) approach to monitor target cell infection by a chimeric vesicular

246 stomatitis virus in which the coat glycoprotein was replaced by the SARS-CoV-2 (Wuhan

247 strain) S protein (VSV-SARS-CoV-2) (Fig.4 and fig. S11) (*35*). This chimeric virus is

248 surface labeled with Atto565-NHS-ester (VSV-SARS-CoV-2-Atto 565) (fig. S11, A and B)

249 and encodes a soluble eGFP that is expressed by infected cells. ACE2-expressing Vero cells

250 that ectopically express TMPRSS2 protease (Vero TMPRSS2) were used as host cells. LLSM

251 imaging revealed Atto 565-labeled viruses on cell surfaces at the earliest time points (Fig. 4,

252 A to D, I, trajectories of viruses shown in magenta, light and dark blue). Single stepwise

253   decreases in fluorescence intensity, corresponding to 25-30% of the total Atto 565

254   fluorescence, were observed for cell surface virus (Fig. 4, B to D, I, t2 to t3, magenta). As

255   these step wise decreases are dependent on the presence of TPMRSS2 (*35*) and are also

256   blocked by pharmacological inhibition of TMPRSS2 (Fig. 4J, central panel), they likely result

257   from TMPRSS2 protease activity and, correspondingly, reflect S1 dissociation after S2'

258   cleavage. A subset of labeled chimeric viruses were internalized via endocytosis within a

259   recorded 10-min time series (Fig. 4, A to D, I, trajectories of viruses shown in light and dark

260   blue), followed by fluorescence-spreading, indicative of membrane fusion within the

261   endosome (Fig. 4, B to D, I, t5 to t6, dark blue; see method). Under the conditions used in

262   these experiments (*35*), spreading of Atto 565 was not observed on the cell surface.

263   VSV-SARS-CoV-2-Atto 565 chimeric virus infectivity of Vero TMRSS2 cells was

264   potently neutralized by its pre-incubation with SP1-77 IgG (IC$_{50}$ ~15 ng/ml) (fig. S11E). Pre-

265   incubation of VSV-SARS-CoV-2-Atto 565 with 500 ng/ml of SP1-77 did not appreciably

266   impact its binding to the Vero TMPRSS2 cell surface (Fig. 4, E to I, trajectories of viruses

267   shown in magenta and light blue). This finding is consistent with the SP1-77 footprint lying

268   outside of the RBM and the inability of SP1-77 to block ACE2 engagement (Fig. 3C, fig. S6,

269   C and D).   In addition, pre-incubation with SP1-77 greatly diminished the number of Atto

270   565 fluorescence intensity step decreases of chimeric virus at the cell surface (Fig. 4, F to J, t2

271   to t3). This result indicates either the blockage of S2' cleavage and/or inhibition of S1

272   dissociation. While pre-incubation of viruses with SP1-77 had modest impact on virus

273   endocytosis (Fig. 4, F to I, trajectories of viruses shown in light blue), it dramatically

274   inhibited fluorescence-spreading within the endosome --indicative of viral-endosomal

275   membrane fusion block (Fig. 4, F to J). Together, these findings suggest that SP1-77

276   neutralizes the SARS-CoV-2 by blocking membrane fusion (Fig. 4, I and J). For comparison,

277   LLSM single virion visualization revealed that pre-incubation with 500 ng/ml of our VHH7-5-

278   82 antibody fully blocked binding of the chimeric virus to the cell surface (Fig. 4J), consistent

279   with our findings that the VHH7-5-82 footprint overlaps with the RBM (fig. S6A).

280   To distinguish between the possible effect of SP1-77 on cleavage of S2' versus

281   dissociation of S1, we reconstructed these two processes *in vitro*. Activation of VSV-SARS-

282   CoV-2-Atto 565 by brief treatment with trypsin for 30 minutes followed by the addition of the

283   trypsin inhibitor aprotinin bypasses the requirement for host cell proteases TMPRSS2 and

284   cathepsin L for infection, which indicates cleavage of the S2' site by trypsin treatment (*35,*

285   *36*). Incubation of the trypsin-activated virus with recombinant ACE2 induces a signal

286   decrease of ~75% of the total Atto565 fluorescence, as quantified by single particle imaging;

287   while cleavage by trypsin alone or incubation with ACE2 alone does not induce this signal

288   decrease (fig. S11, C and D). Assuming that an ~ 75% signal decrease *in vitro* reflects

289   complete S1 dissociation from VSV-SARS-CoV-2 virus, then the corresponding 25-30 %

290   signal decrease *in vivo* likely reflects S1 dissociation for a subset of spike proteins when the

291   virus is attached to the cell surface (Fig. 4, B to D, t2 to t3). In contrast, the decrease in signal

292   no longer occurred when trypsin-activated VSV-SARS-CoV-2-Atto 565 was incubated with

293   SP1-77 and then exposed to ACE2 (Fig. S11, C and D). This finding indicates that SP1-77

294   inhibits ACE2-induced dissociation of S1 from the pre-cleaved S1/S2 complex. Finally, the

295   SP1-77 Fab also inhibits S1 dissociation in this assay and, corresponding, robustly neutralizes

296   VSV-SARS-CoV-2 virus (fig. S11, D and E). This finding indicates that SP1-77 can achieve

297   it neutralization activity by blocking S1 dissociation via a monovalent interaction. See fig.

298   S12 for a model of the SP1-77 neutralization mechanism.

299

DISCUSSION

301   The RBD epitope targeted by SP1-77 overlaps very modestly with that of the LY-

302   CoV1404 (Bebtelovimab) SARS-CoV-2 neutralizing nAb that is currently approved for

303   therapeutic use. The RBD-binding site of LY-CoV1404 includes the 440-445 segment of the

304   RBD that is also bound by SP1-77 (*37*) (Fig. 3C). Like SP1-77, LY-CoV1404 potently

305   neutralizes all currently known VOCs. However, the bulk of the LY-CoV1404 footprint

306   overlaps with the RBM, which mechanistically allows LY-CoV1404 to achieve neutralization

307   by blocking ACE2 binding (*37*). Like SP1-77, the S309 nAb and its Sotrovimab derivative

308   previously used therapeutically bind outside of the RBM (*17*). However, S309 is quite

309   distinct from SP1-77 in that it fails to neutralize Omicron BA.2 and is less potent than SP1-77

310   in neutralizing other VOCs (*38*). In this regard, the S309 footprint covers both the 339-346

311   and 440-451 segments that are also in the SP1-77 footprint, with the long axis of the S309

312   footprint aligning along the exposed ridge of the RBD in the closed S trimer (Fig. 3C).

313   Notably, however, the same axis of the SP1-77 footprint is almost perpendicular to that of

314   S309, which makes it possible for SP1-77 to reach the NTD (Fig. 3B). Indeed, SP1-77 has a

315   unique binding mode, not seen among any of the previously characterized SARS-CoV-2

316   nAbs, that may underlie its robust and broadly potent neutralization activity.

317   The SP1-77 neutralization mechanism we describe provides the first insight into how a

318   non-ACE2 blocking antibody can potently neutralize SARS-CoV-2.   Besides S309, several

319   other Omicron sub-variant nAbs that have binding epitopes outside of the RBM have been

320   reported very recently (*8, 39*). However, like S309, the mechanism by which these antibodies

321   neutralize SARS-CoV-2 has not been described. The LLSM-based approach we employed to

322   elucidate the novel SP1-77 mechanism should be readily applicable for mechanistic studies of

323   other neutralizing antibodies that do not function via an ACE2 blocking mechanism. The unique

324   binding characteristics and novel neutralization mechanism of the SP1-77, coupled with its broad

325   and potent neutralization of SARS-CoV-2 variants, suggests that it could be a therapeutic against

326   current and, very likely, newly-arising VOCs. Also, SP1-77 might be useful in a cocktail with

327   other nAbs, such as LY-CoV1404, that potently neutralize all tested VOCs through an ACE2-

328   blocking mechanism. In addition, the novel neutralization mechanism of SP1-77 may inspire the

329   design of new vaccine strategies to more broadly target BA.2 and other VOCs.

330   The use of a solely human V_H1-2-rearranging mouse to obtain SP1-77 posed a rigorous

331   test for this class of mouse model. In this regard, all 9 well-characterized V_H1-2-based SARS-

332   CoV-2 neutralizing antibodies isolated from prototype SARS-CoV-2 virus-infected human

333   patients bind a similar epitope on the spike protein RBD domain (*15, 16, 22, 40-44*) (fig. S13, A

334   and B). None of these antibodies tested neutralized Beta, Gamma or Omicron variants, due to

335   their sensitivity to the E484K/A mutation in these variants (*15, 16, 22, 40-44*). Indeed, the

336   striking binding and neutralization similarities of these 9 V_H1-2-based nAbs suggested that most

337   V_H1-2-based SARS-CoV-2-neutralizing antibodies in infected humans are selected by a common

338   prototype neutralization pathway mediated by predisposition of the germline-encoded V_H1-2

339   variable region to bind to the RBD (*22*). Notably, the footprints of our 3 V_H1-2-based SARS-

12

340   CoV-2 nAbs are distinct from those of the 9 well-characterized V_H1-2 based SARS-CoV-2 nAbs

341   isolated from human patients. Thus, our solely V_H1-2-rearranging mouse model permits isolation

342   of human V_H1-2-based SARS-CoV-2 nAbs with novel binding characteristics relative to those

343   derived from patients, potentially by placing greater emphasis on the contribution of CDR3 with

344   respect to diversification of the primary BCR repertoire.

345   The V_H1-2/$V\kappa1$-33-rearranging mouse model has served as a very successful prototype

346   for documenting the potential utility of this humanized antibody-discovery approach by

347   providing the broad, potent, and mechanistically-distinct SP1-77 nAb. Going forward, this type

348   of mouse model could be readily extended to other human V_H and V_L segments, to augment its

349   potential beyond that which we demonstrate in this striking initial study. Finally, this new

350   approach for induction of humanized antibodies from mice could help in the generation of novel

351   therapeutic antibodies and vaccine strategies against other diverse pathogens for which rare

352   cross-reactive neutralizing antibodies are needed such as HIV-1 and influenza.

353

354   **References**

355

356   1.   E. Cameroni *et al.*, Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron
357   antigenic shift. *Nature* **602**, 664-670 (2022).
358   2.   Y. Cao *et al.*, Omicron escapes the majority of existing SARS-CoV-2 neutralizing
359   antibodies. *Nature* **602**, 657-663 (2022).
360   3.   L. Liu *et al.*, Striking antibody evasion manifested by the Omicron variant of SARS-
361   CoV-2. *Nature* **602**, 676-681 (2022).
362   4.   M. McCallum *et al.*, Structural basis of SARS-CoV-2 Omicron immune evasion and
363   receptor engagement. *Science* **375**, 864-868 (2022).
364   5.   W. Dejnirattisai *et al.*, SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from
365   neutralizing antibody responses. *Cell* **185**, 467-484 e415 (2022).
366   6.   T. Zhou *et al.*, Structural basis for potent antibody neutralization of SARS-CoV-2
367   variants including B.1.1.529. *Science*, eabn8897 (2022).
368   7.   K. Khan *et al.*, Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited
369   neutralizing immunity. *bioRxiv: the preprint server for biology* (2022).
370   8.   Y. Cao *et al.*, BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron
371   infection. *bioRxiv: the preprint server for biology* (2022)
372   9.   H. Tegally *et al.*, Continued Emergence and Evolution of Omicron in South Africa: New
373   BA.4 and BA.5 lineages. *bioRxiv: the preprint server for biology* (2022)
374   10.   P. Zhou *et al.*, A pneumonia outbreak associated with a new coronavirus of probable bat
375   origin. *Nature* **579**, 270-273 (2020).

376   11.   M. Hoffmann, H. Kleine-Weber, S. Pohlmann, A Multibasic Cleavage Site in the Spike
377   Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells. *Mol Cell* **78**,
378   779-784 e775 (2020).

379   12.   D. Wrapp *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion
380   conformation. *Science* **367**, 1260-1263 (2020).

381   13.   M. Hoffmann *et al.*, SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is
382   Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278 (2020).

383   14.   C. B. Jackson, M. Farzan, B. Chen, H. Choe, Mechanisms of SARS-CoV-2 entry into
384   cells. *Nat Rev Mol Cell Biol* **23**, 3-20 (2022).

385   15.   J. Hansen *et al.*, Studies in humanized mice and convalescent humans yield a SARS-
386   CoV-2 antibody cocktail. *Science* **369**, 1010-1014 (2020).

387   16.   C. O. Barnes *et al.*, SARS-CoV-2 neutralizing antibody structures inform therapeutic
388   strategies. *Nature* **588**, 682-687 (2020).

389   17.   D. Pinto *et al.*, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV
390   antibody. *Nature* **583**, 290-295 (2020).

391   18.   K. J. Jackson, M. J. Kidd, Y. Wang, A. M. Collins, The shape of the lymphocyte receptor
392   repertoire: lessons from the B cell receptor. *Front Immunol* **4**, 263 (2013).

393   19.   J. Glanville *et al.*, Precise determination of the diversity of a combinatorial antibody
394   library gives insight into the human immunoglobulin repertoire. *Proc Natl Acad Sci U S*
395   *A* **106**, 20216-20221 (2009).

396   20.   W. C. Chen, C. M. Murawsky, Strategies for Generating Diverse Antibody Repertoires
397   Using Transgenic Animals Expressing Human Antibodies. *Front Immunol* **9**, 460 (2018).

398   21.   J. L. Xu, M. M. Davis, Diversity in the CDR3 region of V(H) is sufficient for most
399   antibody specificities. *Immunity* **13**, 37-45 (2000).

400   22.   M. Rapp *et al.*, Modular basis for potent SARS-CoV-2 neutralization by a prevalent
401   VH1-2-derived antibody class. *Cell Rep* **35**, 108950 (2021).

402   23.   M. Tian *et al.*, Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse
403   Precursor Repertoires. *Cell* **166**, 1471-1484 e1418 (2016).

404   24.   S. Jain, Z. Ba, Y. Zhang, H. Q. Dai, F. W. Alt, CTCF-Binding Elements Mediate
405   Accessibility of RAG Substrates During Chromatin Scanning. *Cell* **174**, 102-116 e114
406   (2018).

407   25.   C. Guo *et al.*, CTCF-binding elements mediate control of V(D)J recombination. *Nature*
408   **477**, 424-430 (2011).

409   26.   Y. Xiang, S. K. Park, W. T. Garrard, A major deletion in the Vkappa-Jkappa intervening
410   region results in hyperelevated transcription of proximal Vkappa genes and a severely
411   restricted repertoire. *J Immunol* **193**, 3746-3754 (2014).

412   27.   N. Pishesha *et al.*, A class II MHC-targeted vaccine elicits immunity against SARS-CoV-
413   2 and its variants. *Proc Natl Acad Sci U S A* **118**, (2021).

414   28.   N. K. Routhu *et al.*, SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052
415   protects from SARS-CoV-2 infection and immune pathology in the lung. *Nat Commun*
416   **12**, 3587 (2021).

417   29.   A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: algorithms for
418   rapid unsupervised cryo-EM structure determination. *Nature methods* **14**, 290-296
419   (2017).

420   30.   Y. Watanabe, J. D. Allen, D. Wrapp, J. S. McLellan, M. Crispin, Site-specific glycan
421   analysis of the SARS-CoV-2 spike. *Science* **369**, 330-333 (2020).

422   31.   Organization, W.H. Tracking SARS-CoV-2 variants. (2021)
423   32.   Organization, W.H. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of
424   Concern. (2021).
425   33.   Y. Hirotsu *et al.*, SARS-CoV-2 Omicron sublineage BA.2 replaces BA.1.1: Genomic
426   surveillance in Japan from September 2021 to March 2022. *J Infect*, (2022).
427   34.   J. Zhang *et al.*, Structural and functional impact by SARS-CoV-2 Omicron spike
428   mutations. *Cell Rep* **39**, 110729 (2022).
429   35.   A. J. B. Kreutzberger *et al.*, SARS-CoV-2 requires acidic pH to infect cells. *bioRxiv: the
430   preprint server for biology* (2022)
431   36.   S. Belouzard, V. C. Chu, G. R. Whittaker, Activation of the SARS coronavirus spike
432   protein via sequential proteolytic cleavage at two distinct sites. *Proc Natl Acad Sci U S A*
433   **106**, 5871-5876 (2009).
434   37.   K. Westendorf *et al.*, LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2
435   variants. *bioRxiv : the preprint server for biology*, (2022).
436   38.   S. Iketani *et al.*, Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
437   *Nature*, (2022).
438   39.   F. Muecksch *et al.*, Increased Memory B Cell Potency and Breadth After a SARS-CoV-2
439   mRNA Boost. *Nature*, (2022).
440   40.   L. Liu *et al.*, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2
441   spike. *Nature* **584**, 450-456 (2020).
442   41.   M. A. Tortorici *et al.*, Ultrapotent human antibodies protect against SARS-CoV-2
443   challenge via multiple mechanisms. *Science* **370**, 950-957 (2020).
444   42.   D. F. Robbiani *et al.*, Convergent antibody responses to SARS-CoV-2 in convalescent
445   individuals. *Nature* **584**, 437-442 (2020).
446   43.   M. Yuan *et al.*, Structural and functional ramifications of antigenic drift in recent SARS-
447   CoV-2 variants. *Science* **373**, 818-823 (2021).
448   44.   W. Dejnirattisai *et al.*, The antigenic anatomy of SARS-CoV-2 receptor binding domain.
449   *Cell* **184**, 2183-2200 e2122 (2021).
450

Acknowledgements

461   (A.J.B.K). Live virus neutralization assays were performed under the direction of Dr. Thomas

462   Oguin, III in the Virology Unit of the Duke Regional Biocontainment Laboratory (RBL), which

463   received partial support for construction from the National Institutes of Health, National Institute

464   of Allergy and Infectious Diseases (UC6-AI058607; G20-AI167200; G.S.). The funders had no

465   role in study design, data collection and analysis, interpretation, writing, decision to publish, or

466   preparation of the manuscript. The content of this publication does not necessarily reflect the

467   views or policies of the Department of Health and Human Services, nor does mention of trade

468   names, commercial products, or organizations imply endorsement by the U.S. Government.

469   **Author contributions:** S.L. and F.W.A. initiated and oversaw this overall study. S.L.,

470   T.K., A.K. B.C., B.F.H. and F.W.A. designed the experiments. S.L. and H.D. generated the

471   mouse model. S.L., C.J., and M.T. performed immunizations, generated the antibodies, and

472   characterized the antibodies. K.S. provided the spike immunogen and N.P. and H.P. provided the

473   VHH7-RBD immunogen. R.P., M.B. and S.L. performed binding experiments. D.M., A.E., S.K.

474   and L.B. performed the pseudovirus neutralization experiments. G.S. performed the PRNT

475   neutralization experiments. M.A. and K.C. performed the SPR binding and competition analyses.

476   R.E. and K.M. performed the NSEM experiments and interpreted that data. J.Z., Q.P. and B.C.

477   performed the Cryo-EM experiments and interpreted the data. A.K., A.S. and T.K. performed the

478   live imaging experiment with lattice light sheet microscopy and interpreted their findings in the

479   context of the neutralization mechanism. A.Y.Y. performed the CDR3 diversity analyses.

480   A.C.W. performed ES cell injections. L.V.F. collected blood samples and performed mouse

481   maintenance. S.L., J.Z., A.K. T.K., B.C., B.F.H. and F.W.A. designed figures and wrote the

482   manuscript. All other authors including helped polish the manuscript.

483   **Competing interests:** M.T. and F.W.A. are authors on a patent application that

484   describes the general type of mouse model used (US 16/973,125). S.L., B.F.H. and F.W.A. are

485   authors on patent applications describing the antibodies reported (63/256,384 and 63/305,424).

486   **Data and materials availability:** All newly created data and materials described in this

487   manuscript will be available from the corresponding author upon reasonable request. Nucleotide

488   sequences have been deposited to GenBank (accession Nos. ON568518 to ON568583). NSEM

489   reconstructions generated during this study are available at EMD-27043, EMD-27044 and EMD-

16

490   27046. Cryo-EM reconstructions and atomic models generated during this study are available at

491   the PDB and EMBD databases under the following accession codes: 7UPW,7UPX,7UPY, EMD-

492   26676 (three RBD-down D614G spike in complex with SP1-77 Fabs), EMD-26677 (local

493   refinement of RBD in complex with SP1-77 fab), EMD-26678 (one RBD-up D614G spike in

494   complex with SP1-77 Fabs). The next-generation sequencing data reported in this paper have

495   been deposited in the Gene Expression Omnibus (GEO) database under GSE197255. This work

496   is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which

497   permits unrestricted use, distribution, and reproduction in any medium, provided the original

498   work is properly cited. To view a copy of this license, visit

499   https://creativecommons.org/licenses/by/4.0/. This license does not apply to

500   figures/photos/artwork or other content included in the article that is credited to a third party;

501   obtain authorization from the rights holder before using such material.

502

503   **Figure Legends.**

504

505   **Figure 1. A humanized mouse model with diverse BCR repertoire derived from single**

506   **human V_H and Vκ recombination.** (**A**) Schematic representation of genetic modifications in

507   the *Igh* and *Igκ* locus of V_H1-2/Vκ1-33-rearranging mouse model. The V_H1-2^{IGCR1Δ} allele was

508   made previously (*23*). We deleted 2MB region upstream of V_H1-2 that contains all the mouse

509   V_Hs to generate V_H1-2$^{mVHΔ/IGCR1Δ}$ allele. We replaced mouse Vκ3-2 to human Vκ1-33 and

510   deleted the Cer/sis element in Vκ to Jκ interval to generate Vκ1-33^{CSΔ} allele. (**B**) HTGTS-rep-

511   seq analysis of Vκ usages in 129/Sv wild-type (left panel) and Vκ1-33-rearranging mouse

512   splenic B cells in presence (middle panel) and absence (right panel) of Cer/sis element. The x

513   axis lists all functional Vκs from the distal to the *Jκ*-proximal end. The histogram displays the

514   percent usage of each Vκ among all productive VκJκ rearrangements. The junction number of

515   each Vκ was shown in table S1. (**C-D**) The length distribution of V_H1-2 HC CDR3 (left panel in

516   (**C**)) and Vκ1-33 LC CDR3 (left panel in (**D**)) in splenic B cells. Data are mean ± SD of three

517   libraries from different mice. Venn diagram shows the V_H1-2 HC CDR3 (right panel in (**C**)) and

518   Vκ1-33 LC CDR3 (left panel in (**D**)) complexity. The unique reads derived from the same

17

519   libraries in the left panel. Little overlap of V_H1-2 HC CDR3 sequences among three independent

520   mice indicates tremendous CDR3 complexity.

521

522   **Figure 2. Immunizing the mouse model with SARS-CoV-2 spike or RBD elicited potent and**

523   **broad V_H1-2/Vκ1-33 antibodies.** (**A**) Immunization scheme. Prime plus boost immunizations

524   were performed at an interval of four weeks. (**B**) Table shows the V_H1-2/Vκ1-33 antibodies

525   isolated from SARS-CoV-2 spike-specific or RBD-specific IgG$^+$ B cells. The antibody

526   sequences and sequence features were shown in table S2. (**C**) Table shows the neutralization

527   activities of three mAbs against VOCs and VOIs in pseudovirus neutralization assays.

528   Experiments were done in 293T/ACE2 cells. The data are also shown in fig. S4, A and B. Data

529   are representative of 2 biologically independent experiments for most VOCs and VOIs, but one

530   experiment for BA.2 and BA.3. Each independent experiment contains 2 technical replicates.

531   IC$_{50}$ values were color-coded based on the key shown at the right. (**D**) Table shows the

532   neutralization activities of three mAbs against VOCs in PRNT live virus neutralization assays.

533   Data are representative of one independent experiment with 2 technical replicates. IC$_{50}$ and IC$_{90}$

534   values were color-coded based on the key shown at the right.

535

536   **Figure 3. cryo-EM structures of SP1-77 Fab in complex of a full-length SASR-CoV-2 S**

537   **trimer.** (**A**) Cryo-EM structures of the SP1-77 Fabs in complex with the full-length S trimer in

538   the one-RBD-up (2.9Å) and three-RBD-down (2.7Å) conformations, respectively. The EM

539   density is colored in gray and the structures are represented in ribbon diagram with the RBD in

540   blue, the NTD in yellow and the rest in dark gray. The heavy chain of SP1-77 is shown in green

541   and the light chain is shown in cyan. There are three SP1-77 Fabs bound to one S trimer in both

542   conformations. (**B**) Close-up view of the interactions between SP1-77 Fab and the RBD and

543   NTD of the S trimer in the RBD-down conformation. Left, the HC CDR3 of SP1-77 makes the

544   main contact with the RBD, with which away from receptor binding motif (RBM) colored in

545   light blue, while the HC CDR2 touches the N-linked glycan from the NTD. Right, zoom-in

546   views of the binding interface, showing the 17-residue HC CDR3 wedging into a groove formed

18

547   by two segments of residues 339-346 and residues 440-445, respectively. The Asn343 glycan of

548   the RBD also interacts with Tyr99 from HC CDR3. Two glycans at Asn122 and Asn165 in the

549   NTD are in proximity to the HC CDR2 (Asn53, Ser54, Gly56, Thr57 and Asn58) and HC FW3

550   (Thr73, Ser74 and Ile75). (**C**) Comparison of binding mode and footprint of SP1-77 with ACE2

551   and other known neutralizing antibodies, including S309 and LY-CoV1404. Left, the RBD

552   domain is in surface representation in gray. ACE2 and the antibodies in ribbon diagram with

553   SP1-77 in green, S309 in orange, LY-CoV1404 in magenta and ACE2 in pink. Right, footprints

554   on the RBD of various antibodies with the one for SP1-77 outlined in green, S309 in orange and

555   LY-CoV1404 in magenta. The interface residues of the SP1-77 are indicated with the major

556   contacting residues highlighted in red.

557

558   **Figure 4. LLSM single virus tracking reveals SP1-77 inhibits S-fragment shedding and**

559   **membrane fusion.** (**A-I**) Trajectories of VSV-SARS-CoV-2-Atto 565 virus imaged every 4 sec

560   with volumetric LLSM beginning 5 minutes after the start of a 4-min inoculation of Vero

561   TMPRSS2 cells with virus at MOI ~ 2 without antibody treatment (**A-D**) or treated with 500

562   ng/mL SP1-77 (**E-H**). Trajectories color coded magenta when virus is localized to the cell

563   surface, light blue when the virus internalizes into the cell, and dark blue if the Atto 565 signal is

564   observed to spread from a point spread function (PSF) to a larger distribution indicating fusion of

565   the viral envelope with an endosomal membrane. Single virus trajectories (**B, F**) with insets

566   showing x-axis projection through 4 planes (top), 3D integrated intensity profiles shown in (**C,**

567   **G**, bottom panel) and corresponding heat maps of fluorescence intensities from 4 plane z-

568   projections in (**C, G**, top panel). Intensity line-profiles through the center of virions (**D, H**)

569   appears as a single point spread function at the cell surface and in endosomes in the absence (**D**,

570   t1-t4) of antibody or its presence (**H**, t1-t6) and which spreads out upon fusion of the virus

571   envelope with endosomal membranes (**H**, t5-t6) in the control. (**I**) Summary of all single virus

572   trajectories over the course of two single experiments, in the absence and presence of antibody,

573   each from 3 cells imaged consecutively for 10 min. Red dots indicate virus trajectories where a

574   TMPRSS2 dependent stepwise drop of Atto 565 signal was observed to occur which indicates

575   release of a fragment of the S-protein. (**J**) Quantification of 5 experiments for each condition for

576   the number of viruses in the total cell volume of every cell imaged (left), the number of Atto 565

577   drops observed in all the trajectories of virus when co-localizing to the cell surface (middle), and

578   how many instances of Atto 565 dye spreading occurs within endosomes which indicated

579   membrane fusion (right).

Figure 1

**A** V_H1-2/$V\kappa$1-33-rearranging mouse model

B

C V_H1-2 HC CDR3

mouse #1: 23,598 junctions
mouse #2: 15,876 junctions
mouse #3: 22,560 junctions

Overlapping of unique V_H1-2 HC CDR3s

D $V\kappa$1-33 LC CDR3

mouse #1: 9,106 junctions
mouse #2: 10,537 junctions
mouse #3: 10,605 junctions

Overlapping of unique $V\kappa$1-33 LC CDR3s

Figure 2

A

Immunogen: 1. 25µg SARS-CoV-2 Spike with Poly I:C
2. 25µg VHH7-RBD with Poly I:C

n=3 (wk0) → wk2 → n=3 (wk4) → wk6 → wk6-8
Blood (wk0), Blood (wk2), Blood (wk6), Spleen IgG+ n=3 (wk6-8)

B

B cell lineage	Immunogen	Cells	HC CDR3	length of HC CDR3	LC CDR3	length of LC CDR3
SP1	SARS-CoV-2 spike	5	ARDRVLYGRSFGWYFDV	17 aa	QQYDNLPT	8 aa
SP2	SARS-CoV-2 spike	4	ARERRVIHYSGILYALDY	18 aa	QQYDNLHMFT	9 aa
SP3	SARS-CoV-2 spike	4	AITGRRPWFPF	11 aa	QQYDYLPYT	9 aa
SP4	SARS-CoV-2 spike	6	ARGERRSWFTY	11 aa	QQYDNLPYT	9 aa
VHH7-3	VHH7-RBD	2	ARDLGDYDAWFAY	13 aa	QQYDNLRWT	9 aa
VHH7-5	VHH7-RBD	3	ARDRVGQRFPY	11 aa	QQYDNLWT	8 aa
VHH7-7	VHH7-RBD	4	ARRNCDY	7 aa	QQYDNLPYT	9 aa
VHH7-8	VHH7-RBD	4	ARGKGGTSWFAY	12 aa	QQYDNLCT	8 aa
VHH7-10	VHH7-RBD	1	ARDPLTGIFDY	11 aa	QQYDNLPYMYT	11 aa

C

Pseudotyped Virus Neutralization of Monoclonal Antibodies (IC$_{50}$: ng/ml)

	Alpha	Beta	Gamma	Epsilon	Iota	Iota_E484K	Delta	Omicron				
G614	B.1.1.7	B.1.351	P.1	B.1.429	B.1.526	B.1.526.E484K	B.1.617.2	BA.1	BA.2	BA.3	BA.4/BA.5	BA.2.12.1
SP1-77	20	28	16	15	36	19	11	76	6.5	33	7	16	8
VHH7-5-82	38	20	>10,000	>10,000	>10,000	26	>10,000	>10,000	>10,000	-	-	-	-
VHH7-7-53	68	43	>10,000	>10,000	62	43	>10,000	96	>10,000	-	-	-	-

Neutralization titer IC$_{50}$ (ng/ml)
<10
10-100
100-1,000
1,000-10,000
>10,000

D

PRNT Live Virus Neutralization of Monoclonal Antibodies (ng/ml)

	WA1		B.1.1.7		B.1.351		P.1		B.1.617.2	
	Prototype		Alpha		Beta		Gamma		Delta	
Antibody	IC$_{50}$	IC$_{90}$	IC$_{50}$	IC$_{90}$	IC$_{50}$	IC$_{90}$	IC$_{50}$	IC$_{90}$	IC$_{50}$	IC$_{90}$
SP1-77	1.1	2.4	1.1	1.3	0.8	1.1	0.8	1.2	9.7	12.1
VHH7-5-82	910.5	1128.0	111.6	1436.0	>10,000	>10,000	>10,000	>10,000	>10,000	>10,000
VHH7-7-53	136.3	2365.0	58.4	172.6	>10,000	>10,000	>10,000	>10,000	149.3	409.6

Neutralization titer (ng/ml)
<10
10-100
100-1,000
1,000-10,000
>10,000

Figure 3

A

One RBD-up SARS-CoV-2 S trimer

Three-RBD-down SARS-CoV-2 S trimer

Up RBD

NTD

SP1-77 Fab

90°

SP1-77 Fab

B

SP1-77 V$_H$ SP1-77 V$_L$

HC CDR2

HC CDR1

HC CDR3

NTD   RBM   RBD

Arg100A   Asp95

Leu98   Tyr49

Tyr99   Val97

Asn343-glycan   Thr345   Ser100B   Arg346

Tyr32

Arg100A   Asn440

Asp92   Phe100C

Val445   Ser100B   Lys444   Leu441   Asp442

Thr73   Ser54   Asn53

Cys166   Asn165-glycan

Ile75   Ser74

Asn122-glycan

C

LY-CoV1404

SP1-77

ACE2

S309

RBD

445   444

499   450

443   442

440   346

441   345

343   339

340

Asn343-glycan

SP1-77
S309
LY-CoV1404

Figure 4

A — SP1-77

B t1 t2 t3 t4 t5 t6

C t1 t2 t3 t4 t5 t6

D Endosome Fluorescence Spread

E + SP1-77

F t1 t2 t3 t4 t5 t6

G t1 t2 t3 t4 t5 t6

H Endosome Fluorescence Spread

I − SP1-77 / + SP1-77

fusion / endosome / surface

Cell1 Cell2 Cell3

Time post inoculation (s)

J
Viruses associated with the cell — p = 0.0225 — Control, SP1-77, VHH7-5-82

Shedding of S at surface — p < 0.0001 — Control, SP1-77, Camostat Mesylate

Fusion in endosomes — p < 0.0001 — Control, SP1-77

Materials and Methods

Mice and Embryonic Stem Cells

All mouse experiments were performed under protocol 20-08-4242R approved by the Institutional Animal Care and Use Committee of Boston Children's Hospital. Mice were maintained on a 14-h light, 10-h dark schedule in a temperature-controlled environment, with food and water provided ad libitum. ES cells were grown on a monolayer of mitotically inactivated mouse embryonic fibroblasts (iMEF) in DMEM medium supplemented with 15% bovine serum, 20mM HEPES, 1x MEM nonessential amino acids, 2mM Glutamine, 100 units of Penicillin/Streptomycin, 100 mM ß-mercaptoethanol, 500 units/ml Leukemia Inhibitory Factor (LIF).

Generation and Characterization of the V_H1-2/$V\kappa1-33$-rearranging mouse model

All the genetic modifications were introduced into previously generated $V_H1-2^{IGCR1\Delta}$ ES cells (129/Sv and C57BL/6 F1 hybrid background) (*1*), using targeting strategies described previously (*1, 2*). In the *Igh* locus, the deletion of all mouse V_Hs was mediated by two guide RNAs that, respectively, target sequences ~100 bp upstream of the most distal mouse V_H1-86P and ~4.3 kb upstream of the human V_H1-2 that replaced V_H5-2 in this modified ES cell line, respectively. In the *Igκ* locus, the mouse Vκ3-2 segment was replaced with human Vκ1-33 segment with an attached CTCF-binding element (CBE) (atccaggaccagcagggggcgcggagagcaca ca) inserted 50 bp downstream of human Vκ1-33 segment. The Vκ1-33/CBE replacement of Vκ3-2 was mediated by homologous recombination using a PGKneolox2DTA.2 (Addgene #13449) construct and two guide RNAs that target the mouse Vκ3-2 segment. The Cer/sis regulatory element in this ES cell line was deleted via the use of two guide RNAs that target sequences ~60 bp upstream and ~1 kb downstream of Cer/sis. A human TdT gene is expressed in this mouse model. The human TdT cDNA was cloned into CTV (Addgene #15912) construct in which the TdT expression was driven by CAG promotor and followed by a EGFP expression that mediated by an internal ribosome entry site (IRES) (*3*). The TdT expression cassette was inserted into the first intron of mouse Rosa26 gene which is on the same chromosome 6 with *Igκ*

1

locus by homologous recombination. The sequences of guide RNAs used for targeting are listed in table S4. The modifications on the chromosome 12 (the *Igh* loci*)* and chromosome 6 (the *Igκ* and Rosa26 loci) were made independently in two ES clones. We performed blastocyst injection of these two ES clones, respectively, generating the $V_H1-2^{mVHΔ/IGCR1Δ}$ -rearranging mouse model and the $V_H1-2^{IGCR1Δ}/Vκ1-33^{CSΔ}$ -rearranging mouse model. The $V_H1-2^{mVHΔ/IGCR1Δ}/Vκ1-33^{CSΔ}$ - rearranging F1 mice were generated by cross-breeding of these two colonies. We then generated mice that were homozygous for each modification and used these mice for all experiments.

To characterize B cells in the homozygous $V_H1-2^{mVHΔ/IGCR1Δ}/Vκ1-33^{CSΔ}$ -rearranging mouse model, splenocytes were isolated from 5-8 week old mice and stained with the following antibodies: APC anti-B220 (eBioscience 17-0452-83); PE anti-Thy1.2 (eBioscience 12-0902-83); Bv605 anti-IgM (BioLegend 406523); Bv711 anti-IgD (BioLegend 405731).

Splenic B Cell Purification and HTGTS-Rep-seq Analysis

Splenic B cells were purified from 5-8 week old mice by MACS$^®$ Microbeads according to the manufacturer's protocol. In brief, spleens were dissected out from unimmunized mice, prepared into single cell suspensions and incubated with anti-B220 Microbeads for 20 minutes at 4°C. Then, the splenic B cells were collected using the LS column and MACS^{TM} Separater and lysed for genomic DNA extraction. 10 ug of genomic DNA from purified splenic B cells was used for generating HTGTS-rep-seq libraries as previously described (*4*). Four bait primers that target mouse J_H1, J_H2, J_H3 and J_H4 were mixed to capture the *Igh* heavy chain repertoire in one library. Likewise, four 4 bait primers that target mouse Jκ1, Jκ2, Jκ4 and Jκ5 were mixed to capture the *Igκ* light chain repertoire in one library. The sequences of mouse J_H and Jκ primers were as same as the previously reported (*5*). These HTGTS-rep-seq libraries were sequenced by Illumina NextSeq 2 x 150-bp paired end kit and analyzed with the HTGTS-Rep-seq pipeline (*6*).

ELISA

96 well plates (Thermo Fisher 446612) were coated with SARS-CoV-2 spike, RBD, NTD or SARS-CoV-1 spike at 100 ng/well at 4°C overnight, and blocked with blocking buffer (150 mM NaCl, 10 mM NaPO$_4$ pH 7.2, 1% bovine serum albumin) at room temperature for one hour.

Then, the plates were washed with the washing buffer (150 mM NaCl, 10 mM NaPO$_4$ pH 7.2, 0.05% Tween 20) to remove the blocking buffer. Sera were serial diluted from 1:200 in the blocking buffer and added to the plates for 1-hour incubation at room temperature. The plates were washed again with washing buffer. Next ,1:1000 diluted AP-conjugated anti-mouse IgG antibody (Southern Biotech, 1030-04) (Pooled sera: reacts with the heavy chains of mouse IgG1, IgG2a, IgG2b, IgG2c, and IgG3) was added and plates were incubated for 1-hour at room temperature. The plates were washed again and phosphatase substrate (Sigma S0942) was added to each well. The absorbance at 405nm (OD405) was recorded. Background absorbance was determined based on wells blotted with the blocking buffer.

Immunogens and Immunizations

HexaPro Spike immunogen was produced and purified as previously described (*7-10*). HexaPro Spike was stabilized by the introduction of six prolines in the S2 region and contained an HRV 3C-cleavable C-terminal twinStrepTagII-8×His tag to facilitate purification (PMID: 32703906). DNA encoding SARS-CoV-2 HexaPro Spike was synthesized (Genscript) and transiently transfected in FreeStyle 293F cells (Thermo Fisher) using 293Fectin (ThermoFisher). On day 5, cell culture supernatants were harvested by centrifugation of the culture followed by filtering through a 0.8-μm filter. Supernatant was concentrated down to 400 mL and Spike protein was purified by StrepTactin chromatography (IBA) using the manufacturer's buffers. Trimeric spike protein was further purified by Superose 6 size-exclusion chromatography (GE Healthcare) in 10 mM Tris pH 8, 500 mM NaCl. All purification steps were done at room temperature. Purified proteins were quantified and snap frozen in dry ice mixed with ethanol.

The VHH7-RBD immunogen was made as previously described (*11*). Briefly, VHH7-RBD DNA was synthesized (Integrated DNA Technologies) and assembled in the pVRC vector. Constructs were transfected into Expi293 cells (Thermo Fischer Scientific) using Polyethyleneimine "Max" (Polysciences). Cell cultures were maintained in Expi293 Media (Thermo Fischer Scientific) at 37°C for 4 day following transfection. Proteins were harvested by centrifugation at 5,000 Å~ g for 30 min at 4°C, followed by affinity chromatography with HisPur

Ni-NTA Resin (Thermo Fischer Scientific) and size exclusion chromatography with a Hi-Load 16/600 S75 column (Cytivia).

For each immunization, 200 ul of immunogen mix, containing 25 ug of filter-sterilized protein immunogen and 60 ug of Poly I:C in PBS, was injected into the peritoneum of each mouse. 8 weeks old mice were immunized twice with same immunogen, 4 weeks apart. Blood samples were collected one day before the first immunization and two weeks after each immunization. Spleens were collected 3 weeks after the second immunization.

Antigen-specific B Cell Sorting and Single Cell RT-PCR

Mouse spleen samples from immunized mice were processed for single B cell sorting as previously described (*5*). In brief, single cell suspension of splenocytes were stained with several fluorescent antibodies. Antigen-specific IgG$^+$ B cells were selected for the phenotype B220$^+$ (PE-Cy7: BD 552772), IgD$^-$ (BV711: BioLegend 103255), IgG1$^+$ (BV605: BD 563285), IgG2a$^+$ (BV605: BD 564024), Spike$^+$ (Alex647) or RBD$^+$ (Alex647). SARS-CoV2 spike and RBD were conjugated with Alex647 fluorescence (Thermo Fisher A30009).

Single cell RT-PCR was performed as described previously (*1*). In brief, single antigen-specific IgG$^+$ B cells were sorted into 96-well plate that contain 5ul of lysis buffer in each well. After sorting, we used a primer mixture that specifically targets Cu, Cγ1, Cγ2a and Cκ to perform reverse transcription and then two rounds of nested PCR to amplify the V(D)J sequences of rearranged V_H1-2 and Vκ1-33 exons. PCR products were run on agarose gels and subjected to Sanger sequencing to confirm their identity. Primer sequences used are listed in Supplementary table S4.

Monoclonal Antibody and Fab Production

Sequences of paired V_H1-2-based and Vκ1-33 based variable region exons of antigen-specific antibodies were determined by sanger sequencing following single cell RT-PCR (table S2). The DNA fragments containing the heavy-chain and the light-chain variable region exons (table S2), with human constant region sequences (IgG4 or IgG1, Igκ) at the C terminus were synthesized in Integrated DNA Technologies (gblock) and cloned into pcDNA3.4$^+$ plasmids,

4

respectively. Monoclonal antibodies were generated using the Expi293 expression system (Thermo Fisher Scientific) according to the product manual. The antibodies were purified from Expi293 cell supernatant by high-performance liquid chromatography (HPLC) coupled with HiTrap Protein A HP columns (Cytiva, formerly GE Healthcare). Monoclonal antibodies were then dialyzed by SnakeSkin dialysis tubing (10K MWCO, 22 mm) and stored at 4 °C in PBS.

Fabs were made as previously described (*12*). Full-length antibodies were dialyzed into 20 mM sodium phosphate, 10 mM EDTA, pH 7.0 and then concentrated to ~20 mg/ml by centrifugal filtration (Amicon/EMD Millipore). IgG antibodies were digested in 20 mM sodium phosphate, 10 mM EDTA, 20 mM cysteine, pH 7.4 with papain-agarose resin (Thermo Fisher Scientific) for 5 hr at 37°C. The Fab fragments are then separated from non-digested IgG and Fc fragments by a 1 hr incubation with rProtein A Sepharose Fast Flow (GE Healthcare). Post incubation, cystein was removed by centrifugal filtration and buffer exchanged into 1x PBS pH7.4 (Amicon/EMD Millipore).

Plaque Reduction Neutralization Test (PRNT)

SARS-CoV-2 Plaque Reduction Neutralization Test (PRNT) were performed in the Duke Regional Biocontaiment Laboratory BSL3 (Durham, NC) as previously described with virus-specific modifications (*13*). Briefly, two-fold dilutions of a test sample (e.g. serum, plasma, purified Ab) were incubated with 50 PFU SARS-CoV-2 virus (Isolate USA-WA1/2020, NR-52281) for 1 hour. The antibody/virus mixture is used to inoculate Vero E6 cells in a standard plaque assay (*14, 15*). Briefly, infected cultures are incubated at 37°C, 5% CO2 for 1 hour. At the end of the incubation, 1 mL of a viscous overlay (1:1 2X DMEM and 1.2% methylcellulose) is added to each well. Plates are incubated for 4 days. After fixation, staining and washing, plates are dried and plaques from each dilution of each sample are counted. Data are reported as the concentration at which 50% of input virus is neutralized. A known neutralizing control antibody is included in each batch run (Clone D001; SINO, CAT# 40150-D001).

Antibody Affinity and Competition Assays by Surface Plasmon Resonance (SPR)

SPR screening and affinity measurements of monoclonal Fabs binding to SARS-CoV-2 spike proteins were performed using a Biacore S200 instrument (Cytiva, formerly GE Healthcare) in HBS-EP+ 1X running buffer. The SARS-CoV-2 spike (S) proteins with a Strep tag were first captured onto a Streptavidin sensor chip to a level of 200-400 RU. For screenings, the Fabs were injected over the captured S proteins using the high performance injection mode at a flow rate of 30uL/min. Association phase was maintained at 180s injections of each Fab followed by a dissociation of 720s. After each dissociation phase, the S proteins and bound Fabs were removed from the sensor surface using a 30s regeneration pulse of Glycine pH1.5. For affinity measurement, the Fabs were injected over the captured S proteins using single cycle kinetics with the high performance injection mode at a flow rate of 50uL/min. Association phase was maintained at 120s injections of each Fab at increasing concentrations followed by a dissociation of 900s. After each dissociation phase, the CoV-S proteins and bound Fabs were removed from the sensor surface using a 30s regeneration pulse of Glycine pH1.5. Results were analyzed using the Biacore S200 Evaluation software (Cytiva). A blank streptavidin surface along with blank buffer binding were used for double reference subtraction to account for non-specific protein binding and signal drift. Subsequent curve fitting analyses were performed using a 1:1 Langmuir model with a local Rmax for the Fabs or using the heterogeneous ligand model with local Rmax.

Antibody binding competition and blocking were measured by SPR following immobilization by amine coupling of monoclonal antibodies to CM5 and CM3 sensor chips (BIAcore/Cytiva) (*7*). Antibody blocking assays were performed by sequential high performance injections of Spike protein (20 μM) over mAb immobilized surfaces for 3 minutes at 30 μL/min immediately followed by a test Ab (200 μM) for 3 minutes at 30 μL/min. The dissociation of the antibody sandwich complex with the spike protein was monitored for 10 minutes with buffer flow and then a 24 second injection of Glycine pH2.0 for regeneration. Double reference subtraction was used to account for signal drift. Data analyses were performed with BIA-evaluation 4.1 software (BIAcore/Cytiva). The reported competition experiments are representative of two data sets.

6

Pseudovirus Neutralization Tests

The pseudovirus neutralization assay in 293T/ACE2 cells performed at Duke has been described in detail and is a formally validated adaptation of the assay utilized by the Vaccine Research Center; the Duke assay is FDA approved for D614G. For measurements of neutralization, pseudovirus was incubated with 8 serial 5-fold dilutions of antibody samples (1:20 starting dilution using antibodies diluted to 1.0 mg/ml or 0.5 mg/ml) in duplicate in a total volume of 150 µl for 1 hr at 37°C in 96-well flat-bottom culture plates. 293T/ACE2-MF cells were detached from T75 culture flasks using TrypLE Select Enzyme solution, suspended in growth medium (100,000 cells/ml) and immediately added to all wells (10,000 cells in 100 µL of growth medium per well). One set of 8 wells received cells + virus (virus control) and another set of 8 wells received cells only (background control). After 71-73 hrs of incubation, medium was removed by gentle aspiration and 30 µl of Promega 1X lysis buffer was added to all wells. After a 10-minute incubation at room temperature, 100 µl of Bright-Glo luciferase reagent was added to all wells. After 1-2 minutes, 110 µl of the cell lysate was transferred to a black/white plate. Luminescence was measured using a GloMax Navigator luminometer (Promega). Neutralization titers are the inhibitory dilution (ID) of serum samples at which RLUs were reduced by 50% (ID50) compared to virus control wells after subtraction of background RLUs. Serum samples were heat-inactivated for 30 minutes at 56°C prior to assay.

The pseudovirus neutralization assays in 293T/ACE2/TMPRSS2 cells were performed as previously described (*16-18*). Briefly, human codon-optimized cDNA encoding SARS-CoV-2 spike glycoprotein of the WA-1/2020 and variants were synthesized by GenScript and cloned into eukaryotic cell expression vector pcDNA 3.1 between the *BamH*I and *Xho*I sites. Pseudovirions were produced by co-transfection Lenti-X 293T cells with psPAX2(gag/pol), pTrip-luc lentiviral vector and pcDNA 3.1 SARS-CoV-2-spike-deltaC19, using Lipofectamine 3000. The supernatants were harvested at 48h post transfection and filtered through 0.45µm membranes and titrated using 293T/ACE2/TMPRSS2 cells (HEK 293T cells that express ACE2 and TMPRSS2 proteins). For the neutralization assay, 50 µL of SARS-CoV-2 S pseudovirions (counting ~200,000 relative light units) were pre-incubated with an equal volume of medium containing serial dilutions of mAbs at room temperature for 1h. Then 50 µL of virus-antibody

7

mixtures were added to 293T-ACE2-TMPRSS2 cells (10^4 cells/50 µL) in a 96-well plate. The input virus with all SARS-CoV-2 strains used in the current study were the same (2 x 10^5 relative light units/50 µL/well). After a 3 h incubation, fresh medium was added to the wells. Cells were lysed 24 h later, and luciferase activity was measured using One-Glo luciferase assay system (Promega, Cat# E6130). The assay of each serum was performed in duplicate, and the 50% neutralization titer was calculated using Prism 9 (GraphPad Software). Controls included cells only, virus without any antibody and positive sera.

NSEM Methods

To form the Fab-spike complex, Fab was mixed with spike at a 9:1 molar ratio and incubated at 37 °C for 1 h. The complex was then cross-linked for 5 min by diluting to 200 µg/ml spike concentration with 8 mM glutaraldehyde in HBS buffer (20 mM HEPES, 150 mM NaCl, 5 g/dL glycerol, pH 7.4), and then quenched for 5 min by addition of sufficient 1 M Tris stock to give 80 mM final Tris concentration. For negative stain, a portion of the sample was diluted in HBS buffer to 100 or 50 µg/ml and 5 µl applied to a glow-discharged carbon-coated EM grid for 10-12 second, then blotted, and stained with 2 g/dL uranyl formate for 1 min, and then blotted and air-dried. Grids were examined on a Philips EM420 electron microscope operating at 120 kV and nominal magnification of 49,000x, and ~100 images were collected on a 76 Mpix CCD camera at 2.4 Å/pixel. Images were analyzed by 2D class averages and 3D reconstructions calculated using standard protocols with Relion 3.0 (*19*).

Cryo-EM Sample Preparation and Data Collection

Cryo-EM images were acquired on a Titan Krios electron microscope equipped with a Gatan K3 direct electron detector. We used cryo-SPARC (*20*) for particle picking, two-dimensional (2D) classification, three dimensional (3D) classification and refinement. To prepare cryo EM grids, the full-length G614 spike trimer (3.1 mg/ml)(*21*) and the SP1-77 Fab (7 mg/ml) were mixed at a molar ratio of 1:9 and incubated at room temperature for one hour. The complex was purified by gel filtration chromatography on a Superose 6 10/300 column (GE Healthcare, Chicago, IL) in a buffer containing 25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.02%

DDM. Both the mixed complex and purified complex were used for cryo grid preparation. 4.0 μl of the complex was applied to a 1.2/1.3 Quantifoil gold grid (Quantifoil Micro Tools GmbH), which had been glow discharged with a PELCO easiGlow™ Glow Discharge Cleaning system (Ted Pella, Inc.) for 60 s at 15 mA. Grids were immediately plunge-frozen in liquid ethane using a Vitrobot Mark IV (ThermoFisher Scientific), and excess protein was blotted away by using grade 595 filter paper (Ted Pella, Inc.) with a blotting time of 4 s, a blotting force of -12 at 4°C with 100% humidity. The grids were first screened for ice thickness and particle distribution. Selected grids were used to acquire images by a Titan Krios transmission electron microscope (ThermoFisher Scientific) operated at 300 keV and equipped with a BioQuantum GIF/K3 direct electron detector. Automated data collection was carried out using SerialEM version 3.8.6 (*22*) at a nominal magnification of 105,000× and the K3 detector in counting mode (calibrated pixel size, 0.83 Å) at an exposure rate of 13.761 electrons per pixel per second. Each movie add a total accumulated electron exposure of ~53.853 e-/$Å^2$, fractionated in 50 frames. Data sets were acquired using a defocus range of 0.5-2.2 μm.

Image Processing and 3D Reconstructions

Cryo-EM images were first processed in cryoSPARC v.3.3.1.(*20*) with the drift correction performed using the patch mode, and contrast transfer function (CTF) estimated by the patch mode as well. Motion corrected sums with dose-weighting were used for subsequent image processing. Templates for particle-picking were generated from a small number of manually picked particles and the template-based particle picking was then performed for all 28,899 recorded images with 7,657,522 particles extracted in total (box size 672Å, downsizing to 128Å). The particles were subjected to four rounds of 2D classification in cryoSPARC, giving 3,894,421 good particles. A low-resolution negative-stain reconstruction of the Wuhan-Hu-1 (D614) sample was low-pass filtered to 40Å resolution and used as an initial model for 3D classification (*23*). The selected good particles were subjected to two rounds of heterogeneous 3D classification with six copies of the initial model as references in C1 symmetry. One major class (12.8%) with clear structural features was re-extracted to a smaller boxsize (480Å) and subjected to another two rounds of heterogeneous refinement with four

9

copies of the initial model as references in C1 symmetry. There were two major classes, one representing the three-RBD-down S trimer bound with three SP1-77 Fabs and another representing the one-RBD-up S trimer in complex with three SP1-77 Fabs. The first class was subjected to one round of non-uniform refinement in C3 symmetry, giving a map at 2.9Å resolution from 250,319 particles. The second class was refined in C1 symmetry instead, giving a map at 3.1Å resolution from 209,249 particles. To further improve the overall resolution, both classes were subjected to local CTF refinement, resulting in a 2.7Å map for the complex with the S trimer in the three-RBD-down conformation, and a 2.9Å map for a 2.7Å map for the complex with the S trimer in the one-RBD-up conformation. To improve the density for the Fab and RBD, several different local refinements were performed with a soft mask covering a single RBD and the bound Fab. From the three-RBD-down complex, the local refinement gave a map at 3.2Å resolution; from the one-RBD-up complex, the local refinements gave a 3.3Å map for the Fab bound to the RBD in the down conformation, and a 4.8Å map for the Fab bound to the RBD in the up conformation. The best density maps were used for model building.

All resolutions were reported from the gold-standard Fourier shell correlation (FSC) using the 0.143 criterion. Density maps were corrected from the modulation transfer function of the K3 detector and sharpened by applying a temperature factor that was estimated using Sharpening Tools in cryoSPARC. Local resolution was also determined using cryoSPARC.

Model Building

For model building, we used our G614 S trimer structures (PDB ID: 7KRQ and PDB ID: 7KRR (*24*)) as the initial templates for the spike protein, and the S309 antibody structure (PDB ID: 6WS6 (*25*)) for SP1-77 antibody. We predicted the SP1-77 Fab structure by AlphaFold (*26*), largely confirming our model building and the predicted structure also helped further improving some details of the final model. Several rounds of manual building were performed in Coot (*27*). The models were refined in Phenix (*28*) against the 2.7Å (three-RBD-down) and 2.9Å (one-RBD-up) maps, respectively, as well as the 3.2Å map from the masked local refinement using the model containing a single RBD and the SP1-77 Fab. Iteratively, refinement was performed

in both Phenix (real space refinement) and ISOLDE (*29*), and the Phenix refinement strategy included minimization_global, local_grid_search, and adp, with rotamer, Ramachandran, and reference-model restraints, using 7KRQ and 7KRR as the reference model. The refinement statistics are summarized in table S3. Structural biology applications used in this project were compiled and configured by SBGrid (*30*).

Generation and purification of VSV-SARS-CoV-2 chimeras

The generation of recombinant VSV chimeras expressing eGFP where the glycoprotein G was replaced with spike (S) protein Wuhan-Hu-1 strain (VSV-SARS-CoV-2) was previously described (*31*). VSV-SARS-CoV-2 chimera were obtained by infection of MA104 cells. Cells were grown in 15 to 20 150-mm dishes and infected at a multiplicity of infection (MOI) of 0.01. The supernatant containing the virus was collected 72 hours post infection and clarified by centrifugation at 1,000 x g for 10 min at 4^oC. A pellet with virus and extracellular particles was obtained by centrifugation in a Ti45 fixed-angle rotor at 72,000 x g (25,000 rpm) for 2 hours at 4^oC, then resuspended overnight in 0.5 mL PBS at 4^oC. This solution was layered on top of then pelleted through 15% sucrose-PBS solution by centrifugation in a SW55 swinging-bucket rotor at 148,000 x g (35,000 rpm) for 2 hours at 4^oC. The pellet was then resuspended overnight in 0.4 mL PBS at 4^oC, layered on top of a 15 to 45% sucrose-PBS linear gradient and subjected to centrifugation in a SW55 swinging-bucket rotor at 194,000 x g (40,000 rpm) for 1.5 hours at 4^oC. The predominant light scattering band located in the lower one-third of the gradient and containing the virions was removed by side puncture of the gradient tube. Approximately 0.3 ml of this solution was mixed with 25 ml of PBS and subjected to centrifugation in a Ti60 fixed-angle rotor at 161,000 x g (40,000 rpm) for 2 hours at 4^oC. The final pellet was resuspended overnight in 0.2 - 0.5 mL PBS aliquots and stored at -80°C.

VSV-SARS-CoV-2 Atto 565 labeling

Stock concentration of VSV-SARS-CoV-2 at a concentration of ~150 µg/mL viral RNA was conjugated with Atto565-NHS ester (Sigma-Aldrich, cat.72464) as previously described (*32, 33*). Virus stocks in 200 µL were adjusted to 0.1 M NaHCO3 (pH 8.3). Atto565 NHS

11

esters were resuspended in anhydrous DMSO (Sigma) and then aliquoted to and dried down into 0.25 µg/mL stocks under house vacuum and then stored at -20°C. Virus stock was added to dried Atto565 NHS ester and incubated at room temperature for 1 hour in the dark. After 1 hour, Tris pH 8.0 to a final concentration of 200 mM was added to quench the reaction. Free label was then separated from labeled virus using a 0.5 mL Piece Zeba spin desalting column with a 40 kDa molecular weight cut off. Labeled virus was stored at 4°C and used within 1 week of labeling.

Preparation of glass coverslips

VSV-SARS-CoV-2-Atto565 infection were performed on 25 mm #1.5 coverslips bound with polydimethylsiloxane (PDMS) with 3 mm (infection) or 5 mm (uptake) wells as previously described (*31*). After desired wells were punched, PDMS was attached to the top surface of a coverslips previously cleaned by sonication, first in isopropanol for 20 minutes and then in 0.5 M KOH for 20 minutes, followed by extensive washing in MilliQ water, followed by drying for 30 minutes at 90°C. The glass was then firmly pressed to the PDMS sheet, after exposure of the surfaces to air plasma in a PDC-001 plasma cleaner (Harrick Plasma) operating at 750 mtorr and 30W for 2 min. The bonded glass/PDMS was heated at 90°C for 20 min, followed by sterilization by incubation with 70% ethanol for 10 min immediately before plating of cells.

For the single particle tracking LLSM experiments, round #1.5 glass coverslips of 6 mm in diameter) were cleaned by sequential 20 min sonication in toluene, dichloromethane, ethanol, and then water followed by storage in 70% ethanol until used for cell plating.

Single molecule Atto565 dye calibration

VSV-SARS-CoV-2-Atto565 was plated for 10 minutes on glass coated with 0.1 mg/mL of poly-D-lysine for 30 minutes (then extensively washed in PBS) and unbound virus removed by 3 consecutive washes with PBS. Atto 565 signal per virion was determined by Spinning disk was imaged by taking 20 planes in z spaced 0.27 µm apart at 50 ms exposures. The number of Atto 565 dyes per virus was calibrated by increasing the exposure (while maintaining the same laser power) of the virus to 1 second and bleaching the Atto 565 dye. The bleach kinetics of

Atto565 was fit using a step detecting code in MATLAB (*34*) and the intensity of the last step bleach steps of single particles was used to determine the intensity of a single Atto565 dye. The linear relationship between intensity and exposure allowed for this intensity to be used to determine the number of dyes attached to each virus.

Infection assays for VSV-SARS-CoV-2

Infection assays were done with cells plated one day before the experiment and used for the infection assays with a final density of ~ 80% confluency as previously described (*31*). VSV -SARS-CoV-2-Atto 565 was incubated with the indicated concentration of antibody for 1 hour at 37°C. Virus was then added to the cells with indicated concentration of antibody for 1 hour, followed by 3 washes with cell culture media (DMEM, 10% FBS, 25 mM HEPES, pH 7.4), and then incubation for 7 hours at 37°C and 10% CO_2 in DMEM containing 25 mM HEPES, pH 7.4.

At the end of the 7-hr incubation, cells were treated for 30 sec with 5 µg/mL WGA-Alexa647 in PBS to define the cell outline, then fixed with 4% PFA in PBS for 15 minutes at room temperature and imaged within 24 hours using a spinning-disk confocal microscope equipped with a 40x oil NA=1.4 objective (1 pixel = 0.33 µm) to acquire random fields, each containing a Z-stack of 20 consecutive optical planes taken 1 µm apart. Cells were scored as infected if the cytosolic eGFP fluorescence was 1.4 times that of the background of uninfected cells from the control experiment without virus.

Lattice light sheet microscopy

Cells were plated onto 5 mm coverslips in a 35 mm culture dish at 60% confluence the day prior to each experiment. Approximately 10 µl of a solution containing 2.5 µg/mL viral RNA of VSV-SARS-CoV-2-Atto565 (MOI ~2) was added to coverslips placed on a piece of parafilm in a 10 cm petri dish for 4 minutes in DMEM with 25 mM HEPES at pH 7.4. Experiments with SP1-77 or VHH7-5-82 virus was pre-incubated with 500 ng/mL antibody at 37°C for 1 hour then 10 µL of VSV-SARS-CoV-2/antibody solution was added to the coverslip. Wetted Chem wipes were place around the parafilm in the Petri dish to help maintain humidity

of the sample. The cells were imaged in phenol red free media, (FluoBright) supplemented with 5% FBS and 25 mM HEPES, pH 7.4. The samples were volumetrically imaged as a time series using a dithered multi-Bessel lattice light sheet using a sample scan with 0.5 μm spacing between each plane every 4 seconds. Cells were kept at $37^{o}C$ and 5% CO2 for the duration of the experiment and soluble Alexa 549 fluorescent dye at 100 nM added to incubation bath to outline cells in experiments.

Single virus tracking and image analysis

The 3D stacks from the LLSM experiments were deskewed and the diffraction limited spots were detected and tracked using an automated detection algorithm that uses least-squares numerical fitting with a model of the microscope PSF approximated by a 3D Gaussian function and implemented in MATLAB previously developed (*35*). Estimated fluorescence intensities associated with each spot were calculated from the corresponding amplitudes of the fitted 3D Gaussian and compared to single virus bound to poly-D-lysine coated glass imaged under the same condition as the experiments. Tracks of virus were then exported into a custom-made program written in LabView for visualizing trajectories (*32*). Each virus trajectory was visually examined for localization to the cell surface, internalization into the cell, and spreading of the Atto565 dye fluorescence. The virus is 80-100 nm, which makes it a diffraction limited object. The spot limited by the wavelength of the dye being emitted is 300 nm. The endosome is 600 nm and larger. The fusion of the viral envelope to the endosomal membrane is observed by a spreading of the fluorescent signal from a point spread limited object to 500-1000 nm over the endosomal membrane.

S1 dissociation reconstitution

The amount of Atto565 signal per virus was determined using single molecule calibration described above under different treatments to determine the proteolytic and ACE2 requirement for S1 dissociation. VSV-eGFP-SARS-CoV-2-Atto565 was incubated with 1 μg/mL trypsin for 30 minutes at $37^{o}C$ in PBS then the reaction was stopped by the addition of 10 μM Aprotinin final concentration. Virus infection was previously confirmed to no longer require host cell proteases

after trypsin cleavage (*32*). Virus was then bound to poly-D-lysine coated glass single molecule

calibration determine no different in fluorescence between trypsin and non-trypsin treated virus.

Incubating virus with ACE2 for 10 min. at 37°C after trypsin cleavage treatment caused a ~75%

decrease in the number of Atto565 molecules per virus. While treatment with 100 ng/mL of SP1-

77 IgG or SP1-77 Fab after trypsin cleavage prior to ACE2 binding prevented this loss of signal.

References

1. M. Tian *et al.*, Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. *Cell* **166**, 1471-1484 e1418 (2016).
2. H. Q. Dai *et al.*, Loop extrusion mediates physiological Igh locus contraction for RAG scanning. *Nature* **590**, 338-343 (2021).
3. T. H. Thai *et al.*, Regulation of the germinal center response by microRNA-155. *Science* **316**, 604-608 (2007).
4. J. Hu *et al.*, Detecting DNA double-stranded breaks in mammalian genomes by linear amplification-mediated high-throughput genome-wide translocation sequencing. *Nat Protoc* **11**, 853-871 (2016).
5. H. Chen *et al.*, BCR selection and affinity maturation in Peyer's patch germinal centres. *Nature* **582**, 421-425 (2020).
6. S. G. Lin *et al.*, Highly sensitive and unbiased approach for elucidating antibody repertoires. *Proc Natl Acad Sci U S A* **113**, 7846-7851 (2016).
7. D. Li *et al.*, In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. *Cell* **184**, 4203-4219 e4232 (2021).
8. K. O. Saunders *et al.*, Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. *Nature* **594**, 553-559 (2021).
9. D. Wrapp *et al.*, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263 (2020).
10. P. Zhou *et al.*, Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **588**, E6 (2020).
11. N. Pishesha *et al.*, A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants. *Proc Natl Acad Sci U S A* **118**, (2021).
12. M. Bianchi *et al.*, Electron-Microscopy-Based Epitope Mapping Defines Specificities of Polyclonal Antibodies Elicited during HIV-1 BG505 Envelope Trimer Immunization. *Immunity* **49**, 288-300 e288 (2018).
13. J. D. Berry *et al.*, Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. *J Virol Methods* **120**, 87-96 (2004).
14. C. M. Coleman, M. B. Frieman, Growth and Quantification of MERS-CoV Infection. *Curr Protoc Microbiol* **37**, 15E 12 11-19 (2015).
15. J. Kint, H. J. Maier, E. Jagt, Quantification of infectious bronchitis coronavirus by titration in vitro and in ovo. *Methods Mol Biol* **1282**, 89-98 (2015).
16. J. Tang *et al.*, Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients. *Nat Commun* **12**, 1221 (2021).

17. S. Ravichandran *et al.*, Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits. *Sci Transl Med* **12**, (2020).

18. S. N. Neerukonda *et al.*, Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. *PLoS One* **16**, e0248348 (2021).

19. J. Zivanov *et al.*, New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* **7**, (2018).

20. A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nature methods* **14**, 290-296 (2017).

21. J. Zhang *et al.*, Structural impact on SARS-CoV-2 spike protein by D614G substitution. *Science* **372**, 525-530 (2021).

22. D. N. Mastronarde, Automated electron microscope tomography using robust prediction of specimen movements. *Journal of structural biology* **152**, 36-51 (2005).

23. Y. Cai *et al.*, Distinct conformational states of SARS-CoV-2 spike protein. *Science* **369**, 1586-1592 (2020).

24. J. Zhang *et al.*, Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant. *Science* **374**, 1353-1360 (2021).

25. D. Pinto *et al.*, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290-295 (2020).

26. J. Jumper *et al.*, Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583-589 (2021).

27. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. *Acta crystallographica. Section D, Biological crystallography* **66**, 486-501 (2010).

28. P. D. Adams *et al.*, PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta crystallographica. Section D, Biological crystallography* **66**, 213-221 (2010).

29. T. I. Croll, ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. *Acta crystallographica. Section D, Structural biology* **74**, 519-530 (2018).

30. A. Morin *et al.*, Collaboration gets the most out of software. *Elife* **2**, e01456 (2013).

31. A. J. B. Kreutzberger *et al.*, Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease. *J Virol* **95**, e0097521 (2021).

32. A. J. B. Kreutzberger *et al.*, SARS-CoV-2 requires acidic pH to infect cells. *bioRxiv*, (2021).

33. A. H. Abdelhakim *et al.*, Structural correlates of rotavirus cell entry. *PLoS Pathog* **10**, e1004355 (2014).

34. Y. Chen, N. C. Deffenbaugh, C. T. Anderson, W. O. Hancock, Molecular counting by photobleaching in protein complexes with many subunits: best practices and application to the cellulose synthesis complex. *Mol Biol Cell* **25**, 3630-3642 (2014).

35. F. Aguet *et al.*, Membrane dynamics of dividing cells imaged by lattice light-sheet microscopy. *Mol Biol Cell* **27**, 3418-3435 (2016).

Figure S1

Figure S1. Generation of the V_H1-2/Vκ1-33-rearranging mouse model. (**A**) The diagram illustrates the deletion of 2MB upstream region of human V_H1-2 that contain all mouse V_Hs. The deletion was mediated by two gRNAs (green). The deleted allele was screened by PCR. The sequencing result was shown in the bottom. (**B**) The diagram, not drawn to scale, illustrates the restriction digests and Southern probe that were used to differentiate the region before (GL) and after Vκ1-33 replacement. (**C**) Southern analysis of positive Vκ1-33 ES clones that showed in (**B**). (**D**) The diagram illustrates the deleted region of Cer/sis regulatory element targeted by two gRNAs and PCR primers that were used to identify the deleted clones. (**E**) PCR analysis of ES clones with Cer/sis deletion. (**F**) Similarities of amino acid sequences between mouse Js and human Js. Human Js are shown in red, and mouse Js are shown in blue. The alignments between human Js and mouse Js were mainly based on the sequences underlined at 5' end that contribute to the CDR3 sequence. The different amino acids between mouse Js and human Js are filled in grey.

Figure S2

Figure S2. Characterization of the V_H1-2/$V\kappa1$-33-rearranging mouse. (**A**) HTGTS-rep-seq analysis of V_H usage in V_H1-2$^{mVH\Delta/IGCR1\Delta}$-rearranging mouse splenic B cells. The x axis lists all functional V_Hs from the distal to the *D*-proximal end. The histogram displays the percent usage of each V_H among all productive V_HDJ_H rearrangements. (**B**) FACS analyses of splenic B cell and T cell populations from wild-type 129/Sv and V_H1-2/$V\kappa1$-33-rearranging mice. They are representative of three biological replicates.

Figure S3

A

B

C

Binding Assay (EC$_{50}$: ng/ml)

	SARS_CoV-2 Spike	SARS_CoV-2 RBD	SARS_CoV-2 NTD
SP1-77	9	14	>10,000
SP2-125	16	>10,000	>10,000
SP3-46	29	>10,000	>10,000
SP4-87	20	>10,000	>10,000
VHH7-3-66	4	3	>10,000
VHH7-5-82	2	3	>10,000
VHH7-7-53	3	3	>10,000
VHH7-8-59	6	4	>10,000
VHH7-10-19	4	5	>10,000

Binding affinity
EC$_{50}$ (ng/ml)

< 10
10-100
100-1,000
1,000-10,000
>10,000

Figure S3. Immunizing the mouse model with SARS-CoV-2 spike or RBD elicited V$_H$1-2/Vκ1-33 antibodies.
(**A**) Binding curves showing reactivity of sera to SARS-CoV-2 related antigens. The upper panel shows the sera from the SARS-CoV-2 Spike immunized mice at week 0, 2 and 6. The bottom panel shows the sera from VHH7-RBD immunized mice. Data were mean ± SD of three mice. (**B**) Gating strategy for single cell sorting of SARS-CoV2 spike-specific or RBD-specific IgG$^+$ B cells after immunization. The upper panel showed the mice immunized with SARS-CoV2 spike plus poly I:C adjuvant. The bottom panels showed the mice immunized with poly I:C (control) or VHH7-RBD plus poly I:C adjuvant. (**C**) Table shows the binding affinities of nine mAbs to the SARS-CoV-2 spike protein, RBD, NTD. Data are representative of two independent experiments. EC$_{50}$ values were color-coded based on the key shown at the right.

Figure S4

A

B

Pseudotyped Virus Neutralization of Monoclonal Antibodies – 293T/ACE2 (IC$_{80}$: ng/ml)

	Prototype	Alpha	Beta	Gamma	Epsilon	Iota	Iota_E484K	Delta	Omicron				
	G614	B.1.1.7	B.1.351	P.1	B.1.429	B.1.526	B.1.526. E484K	B.1.617.2	BA.1	BA.2	BA.3	BA.4 /BA.5	BA.2.12. 1
SP1-77	47	166	35	81	213	37	29	327	26	82	28	56	37
VHH7-5-82	201	109	>10,000	>10,000	>10,000	128	>10,000	>10,000	>10,000	-	-	-	-
VHH7-7-53	423	363	>10,000	>10,000	315	284	>10,000	792	>10,000	-	-	-	-

Neutralization titer IC$_{80}$ (ng/ml)
< 10
10-100
100-1,000
1,000-10,000
> 10,000

C

Pseudotyped Virus Neutralization of Monoclonal Antibodies – 293T/ACE2/TMPRSS2 (IC$_{50}$: ng/ml)

	Prototype	Alpha	Beta	Gamma	Epsilon	Iota_E484K	Delta	Omicron
	WA-1	B.1.1.7	B.1.351	P.1	B.1.429	B.1.526. E484K	B.1.617.2	BA.1
SP1-77	47	77	13	70	66	16	556	39
VHH7-5-82	82	81	>10,000	>10,000	>10,000	>10,000	>10,000	>10,000
VHH7-7-53	162	127	>10,000	>10,000	126	>10,000	131	>10,000

Neutralization titer IC$_{50}$ (ng/ml)
< 10
10-100
100-1,000
1,000-10,000
> 10,000

D

Pseudotyped Virus Neutralization of Monoclonal Antibodies – 293T/ACE2 (IC$_{50}$: ng/ml)

	Prototype		Delta		Omicron			
	G614		B.1.617.2		B.1.1.529 (BA.1)		BA.2	
	IC$_{50}$	IC$_{80}$	IC$_{50}$	IC$_{80}$	IC$_{50}$	IC$_{80}$	IC$_{50}$	IC$_{80}$
SP1-77 (human J)	26	86	91	207	4	19	19	80
SP1-13 (human J)	28	113	35	249	7	67	40	188
SP1-62 (human J)	28	125	47	282	2	47	48	316
SP1-73 (human J)	44	147	84	350	8	46	41	237
SP1-96 (human J)	22	76	66	166	14	45	30	138

Neutralization titer IC$_{50}$ (ng/ml)
< 10
10-100
100-1,000
1,000-10,000
> 10,000

Figure S4. Neutralization data of three mAbs against SARS-CoV-2 pseudoviruses. (**A**) Neutralization Curves of SARS-CoV-2 pseudoviruses displaying S proteins by three V_H1-2/$V\kappa$1-33 mAbs. Data were done in 293T/ACE2 cells by Montefiori et al. and also shown in Fig. 3C and Fig. S4B. Data are representative of one independent experiments with two technical replicates. (**B**) Table shows the neutralization activity - IC_{80} of three mAbs against VOCs and VOIs in pseudovirus neutralization assays. Experiments were done in 293T/ACE2 cells and also shown in Fig. 3C and Fig. S4A. Data are representative of 2 biologically independent experiments for most VOCs and VOIs, but one experiment for BA.2 and BA.3. Each independent experiment contains 2 technical replicates. IC_{80} values are color-coded based on the key shown at the right. (**C**) Table shows the neutralization activities of three mAbs against VOCs and VOIs in pseudovirus neutralization assays. These assays were done independently in 293T/ACE2/TMPRSS2 cells. Compared to the neutralization data done in 293T/ACE2 cells, IC_{50} values are at the similar levels for all VOC and VOI except Delta which was neutralized less potently. Data are representative of one independent experiment with two technical replicates. IC_{50} values are color-coded based on the key shown at the right. (**D**) Table shows the neutralization activities of humanized SP1-77 and the other 4 antibodies in SP1 clonal lineage against VOCs and VOIs in pseudovirus neutralization assays. These assays were done in 293T/ACE2 cells. Data are representative of two independent experiments. Each independent experiment contains 2 technical replicates. IC_{50} values are color-coded based on the key shown at the right.

Figure S5

A

SARS-CoV-2 Spike

— Fab_SP1-77
— Fab_DH1041
— Fab_VHH7-5-82
— Fab_VHH7-7-53

B

Spike-VHH7-5-82 complex

Top View   Side View

50 Å   50 Å

C

Spike-VHH7-7-53 complex

Top View   Side View

50 Å   50 Å

D

Spike-SP1-77 complex

Top View   Side View

50 Å   50 Å

E

SP1-77   VHH7-5-82   VHH7-7-53

Top View

Side View

50 Å

Figure S5. Negative stain electron microscopy analysis of S complexes with three V$_H$1-2/Vκ1-33 neutralizing antibodies. (**A**) SPR data measuring the binding affinity between monoclonal Fabs and SARS-CoV-2 spike proteins. Each coronavirus spike (S) protein was captured on Streptavidin sensor chip and Fabs were screened at 50nM. A blank streptavidin surface along with blank buffer binding were used for double reference subtraction to account for non-specific protein binding and signal drift. Data is representative of two independent experiments. (**B**) A 3D classification of the spike- VHH7-5-82 complex data, with 158,101 particles sorted into 9 classes, shown in top and side views. (**C**) A 3D classification of the spike- VHH7-7-53 complex data, with 187,262 particles sorted into 12 classes, shown in top and side views. (**D**) A 3D classification of the spike-SP1-77 complex data, with 230,136 particles sorted into 12 classes, shown in top and side views. In the top view of **B-D**, arrows indicate Fabs, and arrowheads indicate weak or partial Fab density; RBDs were visually assessed and assigned as up (U), down (D) or intermediate (I); and the circles indicate the selected (or combined) classes used for the final 3D reconstructions shown in **E**. (**E**) Final 3D reconstructions of Fab-S complexes shown in top view and side view with the S in gray and the Fabs colored (SP1-77: green; VHH7-5-82: blue; VHH7-7-53: magenta).

Figure S6

A

5 views

| Top | Back | Left | Front | Right |

VHH-7-5-82

B

VHH-7-7-53

C

SP1-77

D

Detection Abs or ACE2

ACE2 ●
SP1-77
Negative control

Spike or RBD
SP1-77Abs

SP1-77 – Spike complex

SP1-77 – RBD complex

Figure S6. Three V$_H$1-2/Vκ1-33 neutralizing antibodies bind to distinct regions of RBD. (**A-C**) Binding footprint of Fabs of three V$_H$1-2/Vκ1-33 neutralizing antibodies, VHH7-5-82 (**A**), VHH7-7-53 (**B**), and SP1-77 (**C**) shading on the RBD in surface representation. The RBD surface was represented in 5 views (top, back, left, front and right). Black outline indicates the ACE2 RBM. RBD was shown as gray. (**D**) SP1-77 can not block ACE2 binding to the spike protein and RBD. The left panel showed the diagram of SPR assay. The middle panel showed the binding of ACE2, SP1-77 antibody and negative control (red, green and blue, respectively) to preformed SP1-77 - spike complex. The right panel showed the binding of ACE2, SP1-77 antibody and negative control (red, green and blue, respectively) to preformed SP1-77 - RBD complex.

Figure S7

A

B

25 nm

C

7,657,522 particles from template particle picking

4 rounds of 2D classification

3,849,421 good particles

initial model   6 copies of initial model
                       2 rounds of Heterogeneous refinement

2%   2%   12.8%   3.5%   5%   74.7%

initial model   4 copies of initial model
                       2 rounds of Heterogeneous refinement

2%   42.5%   50.8%   4.7%

Non-uniform Refinement | C1   C3 | Non-uniform Refinement

RBD-down

RBD-up   CTF Refinement   CTF Refinement   90°

90°

2.9Å   3.1Å   2.9Å   2.7Å
              (209,249 particles)   250,319 particles)

Local Refinement   mask   mask   Local Refinement

3.3Å   4.8Å   3.2Å
(RBD-down)   (RBD-up)

Figure S7. Purification of the full-length G614 S trimer/SP1-77 Fab complex and cryo-EM analysis. (**A**) Left, the complex of the full-length G614 S trimer and SP1-77 Fab was resolved by gel-filtration chromatography on a Superose 6 column. First peak, the S trimer-Fab complex used for the cryo-EM study; second peak, the dissociated postfusion S2 trimer mixed with the monomeric S1 in complex with Fab; and third peak, free Fab. Inset, peak fractions were analyzed by Coomassie stained SDS-PAGE. Right, representative motion-corrected micrograph of the vitrified complex purified by gel-filtration chromatography. (**B**) 2D class averages (box dimension: 396Å) of the cryo-EM images of the G614 S trimer/SP1-77 Fab complex from cryoSPARC. (**C**) Data processing workflow for structure determination.

Figure S8

C3 symmetry, RBD-down G614 with SP1-77 Fab
250,319 particles
GSFSC Resolution 2.68Å

C1 symmetry, one RBD-up G614 with SP1-77 Fab
209,249 particles
GSFSC Resolution 2.92Å

C1 symmetry, RBD-down with SP1-77 Fab local refine
250,319 particles
GSFSC Resolution 3.23Å

C1 symmetry, RBD-down with SP1-77 Fab local refine
209,249 particles
GSFSC Resolution 3.31Å

C1 symmetry, RBD-up with SP1-77 Fab local refine
209,249 particles
GSFSC Resolution 4.84Å

Figure S8. Cryo-EM structure validation of the G614 S trimer/SP1-77 Fab complex. FSC curves and the viewing direction distribution plot for the S trimer-Fab complex. From top to bottom: the complex of the G614 S trimer in the three-RBD-down conformation and three SP1-77 Fabs; the complex of the G614 S trimer in the one-RBD-up conformation and three SP1-77 Fabs; masked local refinement of the Fab in complex with the RBD from the G614 S trimer in the three-RBD-down conformation; masked local refinement of the Fab in complex with the RBD in the up conformation from the G614 S trimer in the one-RBD-up state; masked local refinement of the Fab in complex with the RBD in the down conformation from the G614 S trimer in the one-RBD-up state.

Figure S9

A

B

RBD   SP1-77 light chain   RBD-down   RBD-up

SP1-77 heavy chain

C

Asn343-glycan
Arg346
Ser349
Phe347
Phe342

G614 spike RBD interface1

Lys444
Asp442
Val445
Ser438
Asn439
Asn437

G614 spike RBD interface2

Asn82A
Leu82
Met80
Tyr79

SP1-77 VH region

Leu170
Val169
Thr165
Phe166
Val163
His164

SP1-77 CH region

Ala93
Val102
Phe100G
Trp100E
Val97
Phe100C
Tyr99

SP1-77 heavy chain CDR H3

Ser26
Leu33
Trp35
Tyr32
Asn34

SP1-77 light chain interface

Tyr86
Tyr87
Tyr91
Gln90

SP1-77 VL region

Asn158
Gln160
Glu161
Ser162
Val163

SP1-77 CL region

Figure S9. Analysis of the the G614 S trimer/SP1-77 Fab complex structure. (**A**) 3D reconstructions of SP1-77 Fab in complex with the G614 S trimer in the three-RBD-down and one-RBD-up conformations, respectively, are colored according to local resolution estimated by cryoSPRAC. (**B**) 3D reconstructions from masked local refinement of the Fab in complex with a single RBD from the G614 S trimer in the three-RBD-down conformation (left), or the RBD in the up conformation from the G614 S trimer in the one-RBD-up state (middle) or the RBD in the down conformation from the G614 S trimer in the one-RBD-up state (right) are colored according to local resolution estimated by cryoSPARC. (**C**) Representative density in gray surface from EM maps with a resolution better than 3.3Å, primarily focusing on the SP1-77 Fab and its binding interface with the RBD of the G614 S trimer.

Figure S10

Figure S10. Modeled SP1-77 binding site on various SARS-CoV-2 variants. (**A**) The potential footprint of SP1-77 on the modeled RBDs from different SARS-CoV-2 variants in a top view. The RBD is shown in surface representation in gray with the SP1-77 footprint highlighted in green and the mutations in each variant in blue. The Fv region of SP1-77 is shown in ribbon diagram in green. Most mutations on spike variants are not located at the SP1-77 footprint. (**B**) Side view of a selected panel from **A**. (**C**) Structural comparison of the SP1-77 binding interface among the RBDs of wildtype G614, Mu and Omicron variants. The conservative nutation R343K in Mu preserves the salt bridge between the residue 343 in the RBD and the SP1-77 D99. The mutations in Omicron variant reconfigures the local conformation near the N343-glycan, which is on the edge of SP1-77 footprint. The RBD is colored in gray, the SP1-77 heavy chain in green and the light chain in light green. Mutations in the Mu and Omicron variants are shown in stick and ball model in blue.

Figure S11

Figure S11. Single molecule calibration of VSV-SARS-CoV-2-Atto565 virus. (**A**) Example image of Atto 565 fluorescence of virus adsorbed for 10 minutes on a glass coverslip coated with poly-D-lysine coated slides and imaged and imaged with spinning disc confocal microscopy. Photobleaching (**B**), used to determine the intensity of single Atto 565 dye intensities allowed to establish that ~20-40 dyes were attached to each virus. (**C**) Histogram and (**D**) data summary of the number of Atto 565 molecules on VSV-SARS-CoV-2-Atto 565 determined by single molecule counting. Treatments prior to adsorption included none (control), incubation with 1 µg/mL trypsin for 30 min at 37°C, treatment without or with trypsin followed by an incubation with 0.5 µM of recombinant ACE2 for 10 min at 37°C, or treatment with trypsin then incubated with 100 ng/mL SP1-77 IgG or SP1-77 Fab for 1 hour at 37°C followed by incubation with ACE2. (**D**) Statistics are averages of peak distribution determined by a Gaussian fit of 3 independent experiments. (**E**) Infection assays showing neutralization of VSV-SARS-CoV-2-Atto 565 infection with SP1-77 IgG or SP1-77 Fab. A soluble eGFP reporter genetically encoded into this VSV chimera allowed for infection to be determined by fluorescence imaging on a spinning disc confocal microscope as shown in the representative examples obtained 7 hr post infection. Cell outlines were obtained with a WGA-Alexa 647 membrane stain applied to cells immediately prior to fixation. Each condition was measured with 3 independent experiments.

Figure S12

Figure S12. Schematic representation of mechanism of SP1-77 inhibition of SARS-CoV-2 infection. (**A**) Without antibody treatments, the spike protein on the viral surface binds to the ACE2 receptor on the infected cell surface. Membrane fusion is activated either by TMPRSS2 protease on the cell membrane or by cathepsin L protease following endocytosis. Cleavage at the S2' site by these proteases leads to dissociation of the S1 subunit, which exposes the fusion peptide on the S2, facilitating viral-host membrane fusion and viral entry into the infected cells. (**B**) Pre-treatment of the virus with SP1-77, a non-ACE2-blocking antibody, does not appreciably impact binding of viruses to the cell surface and their endocytosis. However, SP1-77 greatly inhibits the dissociation of S1 subunit, thereby, blocking activation of the fusion peptide and membrane fusion. (**C**) Pre-treatment of the virus with VHH7-5-82, an ACE2-blocking antibody, prevents binding of the virus to the cell surface.

Figure S13

A

Name	Heavy V Gene	Light V Gene	CDRH3	CDRL3
SP1-77	IGHV1-2	IGKV1-33	ARDRVLYGRSFGWYFDV	QQYDNLPT
VHH7-5-82	IGHV1-2	IGKV1-33	ARDRVGQRFPY	QQYDNLWT
VHH7-7-53	IGHV1-2	IGKV1-33	ARRNCDY	QQYDNLPYT
Fab2-43	IGHV1-2	IGLV2-14	ARGLGVGCSGGNCYLDYYYMDV	SSYTSSSTWV
Fab2-15	IGHV1-2	IGLV2-14	ARGGSRCSGGNCYGWAYDAFDI	SSYTSSSTFV
S2-M11	IGHV1-2	IGKV3-20	ARAAPFYDFWSGYSYFDY	QQYGSSAWT
H4	IGHV1-2	IGKV2-40	ARVPYCSSTSCHRDWYFDL	MQRIEFPLT
COVOX-316	IGHV1-2	IGLV2-8	ARDMAFSMVRGSFDY	SSYAGSNHWV
C121	IGHV1-2	IGLV2-23	ARAPLFPTGVLAGDYYYYGMDV	CSYAGSSTLV
Fab2-4	IGHV1-2	IGLV2-8	ARDRSWAVVYYYMDV	SSYAGSNNLV
CV05-163	IGHV1-2	IGKV3-11	AREVMVRGALPPYGMDV	QQRSNWPPVT
REGN10989	IGHV1-2	IGLV2-14	ARGSRYDWNQNNWFDP	SSFTTSSTVV

B

Figure S13. Epitope analysis and comparison of the previously characterized V_H1-2-based mAbs. (**A**) Table shows a list of V_H1-2-based mAbs for which high-resolution structures have been published with various HC CDR3s and LCs. The three antibodies identified in our mouse model were labeled in red. (**B**) Comparisons of footprints on RBD between our three antibodies and nine previously characterized V_H1-2-based mAbs. Those nine previously characterized V_H1-2-based mAbs show a similar RBD binding epitope that is distinct from where our three antibodies bind.

Table S1: V usages in splenic B cells measured by HTGTS-Repertoire-seq.

VH1-2^mVHΔ/IGCR1Δ allele			
	#1	#2	#3
VH1-84 (distal)	0	0	0
VH1-82	0	0	0
VH1-80	0	0	0
VH1-78	0	0	0
VH1-77	0	0	0
VH1-76	0	0	0
VH1-75	0	0	0
VH1-74	0	0	0
VH8-12	0	0	0
VH1-69	0	0	0
VH1-66	0	0	0
VH8-11	0	0	0
VH1-64	0	0	0
VH1-63	0	0	0
VH1-62	0	0	0
VH1-62-3	0	0	0
VH1-61	0	0	0
VH1-59	0	0	0
VH1-58	0	0	0
VH8-8	0	0	0
VH1-56	0	0	0
VH1-55	0	0	0
VH1-54	0	0	0
VH1-53	0	0	0
VH1-52	0	0	0
VH8-5	0	0	0
VH1-47	0	0	0
VH1-43	0	0	0
VH1-42	0	0	0
VH1-39	0	0	0
VH1-36	0	0	0
VH1-34	0	0	0
VH1-31	0	0	0
VH1-26	0	0	0
VH1-20	0	0	0
VH1-19	0	0	0
VH1-18	0	0	0
VH1-15	0	0	0
VH1-14	0	0	0
VH1-12	0	0	0
VH1-11	0	0	0
VH1-9	0	0	0
VH15-2	0	0	0
VH10-3	0	0	0
VH1-5	0	0	0
VH1-4	0	0	0
VH10-1	0	0	0
VH6-7	0	0	0
VH6-6	0	0	0
VH6-5	0	0	0
VH6-4	0	0	0
VH6-3	0	0	0
VH12-3	0	0	0
VH13-2	0	0	0
VH3-8	0	0	0
VH9-4	0	0	0
VH3-6	0	0	0
VH3-5	0	0	0
VH7-4	0	0	0
VH14-4	0	0	0
VH7-3	0	0	0
VH9-3	0	0	0
VH9-2	0	0	0
VH9-1	0	0	0
VH14-3	0	0	0
VH11-2	0	0	0
VH11-1	0	0	0
VH3-1	0	0	0
VH4-1	0	0	0
VH14-1	0	0	0
VH2-9	0	0	0
VH5-17	0	0	0
VH5-15	0	0	0
VH5-9-1	0	0	0
VH2-6	0	0	0
VH5-12	0	0	0
VH5-9	0	0	0
VH2-4	0	0	0
VH5-6	0	0	0
VH2-3	0	0	0
VH5-4	0	0	0
VH2-2	0	0	0
hVH1-2 (proximal)	23598	15876	22560
total junctions	23598	15876	22560

	129/Sv wildtype allele			Vκ1-33 allele			Vκ1-33^CSΔ allele		
	#1	#2	#3	#1	#2	#3	#1	#2	#3
VK2-137 (distal)	445	481	752	223	387	368	59	86	147
VK1-135	900	1032	1675	333	634	636	116	174	224
VK1-133	100	116	229	39	104	97	10	13	21
VK1-132	25	22	48	4	24	25	2	5	6
VK14-130	51	70	124	18	58	45	7	10	12
VK17-127	596	606	980	302	525	422	83	128	151
VK14-126	196	283	389	131	209	176	31	59	33
VK11-125	192	219	375	126	192	187	34	52	46
VK9-124	155	172	290	57	153	149	38	33	45
VK9-123	25	44	69	25	41	21	10	14	5
VK1-122	135	143	294	84	127	130	28	22	24
VK17-121	486	451	890	218	490	409	85	133	135
VK9-120	532	599	1019	248	405	372	92	139	102
VK1-117	1090	1237	1938	663	939	879	285	441	400
VK2-112	97	100	188	28	91	55	18	13	16
VK14-111	613	753	1048	231	578	498	73	113	104
VK1-110	996	1098	1709	562	889	888	282	366	332
VK2-109	339	404	600	133	232	236	42	79	62
VK16-104	506	457	847	241	456	388	170	290	246
VK20-101-2	37	40	119	24	52	36	13	13	16
VK14-100	130	137	195	55	107	107	21	37	44
VK1-99	53	56	86	15	36	33	11	10	19
VK12-98	130	128	201	23	86	107	19	30	23
VK10-96	1039	1178	1911	980	1196	1120	297	444	439
VK10-95	209	256	410	188	227	267	63	72	61
VK10-94	284	304	497	225	278	318	78	95	83
VK19-93	582	588	992	185	536	469	153	240	213
VK4-92	93	75	146	41	69	53	17	15	17
VK4-91	90	87	132	42	64	89	21	39	49
VK4-90	61	65	102	57	68	74	29	51	47
VK12-89	140	129	206	73	89	105	21	23	25
VK1-88	197	258	504	136	204	204	75	100	93
VK4-86	126	133	246	75	130	104	37	41	45
VK13-85	123	183	265	0	0	0	0	0	0
VK13-84	128	127	193	0	0	0	0	0	0
VK4-81	125	120	205	54	82	80	29	39	28
VK4-80	200	229	324	50	82	107	33	34	45
VK4-79	208	245	378	79	137	167	38	50	33
VK4-78	51	45	116	29	49	39	12	27	17
VK4-74	206	253	296	136	153	169	42	68	47
VK4-73	155	182	270	102	165	157	57	61	53
VK4-72	297	320	418	205	235	318	137	204	162
VK4-71	78	70	109	52	59	68	28	27	22
VK4-70	234	233	392	118	172	186	34	58	61
VK4-69	183	192	319	83	141	126	44	62	32
VK4-68	238	223	338	62	117	100	44	48	51
VK4-63	15	22	39	8	19	15	4	4	7
VK4-61	163	155	295	101	124	158	70	79	57
VK4-59	330	356	481	89	164	203	65	113	92
VK4-58	25	42	53	22	19	14	13	31	25
VK4-57-1	85	106	139	52	76	71	44	61	109
VK4-57	230	240	369	112	169	208	45	78	60
VK4-55	210	232	320	113	151	166	100	136	130
VK4-53	48	53	101	31	59	40	34	45	70
VK4-51	38	28	60	25	31	26	23	28	31
VK4-50	107	121	212	59	85	90	108	138	117
VK5-48	375	459	693	222	363	390	158	230	223
VK12-46	629	735	1155	307	551	493	424	474	404
VK5-45	69	79	101	0	0	0	0	0	0
VK12-44	844	972	1433	450	729	747	575	725	609
VK5-43	210	226	312	0	0	0	0	0	0
VK12-41	373	419	690	141	351	287	272	354	330
VK5-39	431	478	812	312	373	391	362	469	613
VK12-38	90	74	130	59	79	52	62	65	57
VK5-37	16	22	23	12	18	17	5	19	25
VK18-36	15	17	30	12	13	22	25	15	18
VK8-34	50	46	72	26	29	29	15	21	22
VK7-33	28	19	34	15	25	17	5	11	11
VK6-32	688	788	1269	229	454	484	403	470	407
VK8-30	609	623	982	222	439	398	397	518	614
VK8-29	9	3	12	2	7	11	26	20	34
VK8-28	225	266	384	103	178	182	111	191	170
VK8-27	427	500	842	217	370	309	446	641	639
VK6-25	275	306	410	237	331	301	1208	1759	2097
VK8-24	526	525	971	447	548	542	1197	1886	1869
VK6-23	755	819	1194	349	800	737	941	1388	1422
VK8-21	388	398	625	142	275	237	541	671	666
VK6-20	226	216	348	219	280	217	290	360	509
VK8-19	230	239	365	50	101	97	142	224	190
VK6-17	572	707	980	489	718	600	5863	8648	8797
VK8-16	89	116	123	0	0	0	0	0	0
VK6-15	926	1025	1364	480	791	676	1189	1715	1705
VK6-14	115	133	187	34	89	79	177	257	320
VK6-13	114	114	165	52	111	72	257	413	435
VK3-12	607	585	889	514	475	415	8966	13846	16855
VK3-10	374	476	597	259	346	305	5092	7508	7481
VK3-9	15	11	24	28	13	23	357	486	399
VK3-7	446	485	718	413	407	280	9879	14143	13785
VK3-5	385	471	652	324	404	352	5509	8348	8342
VK3-4	671	786	1134	681	687	684	8721	12527	12524
VK3-3	32	31	40	30	25	32	533	827	674
hVK1-33	727	839	1348	298	560	486	9106	10537	10605
VK3-1 (proximal)	128	151	255	104	163	126	6817	8809	6440
total junctions	24131	26612	41335	13588	20741	19539	73015	102778	103146

Table S2: Sequence features of Anti-SARS-CoV-2 antibodies isolated from mouse model with single human V rearrangement.

mAb ID	mAb ID on the Patent	B cell lineage	Immunogen	Human VH	Mouse JH	HC CDR3	VH-SHM (Amino Acid)	Human VK	Mouse JK	LC CDR3	VK-SHM (Amino Acid)
SP1-77	SPIKE-BC1-7-7			hVH1-2	mJH1	ARDRVLYGRSFGWYFDV	8	hVK1-33	mJK2	QQYDNLPT	3
SP1-13	SPIKE-BC1-1-3			hVH1-2	mJH1	ARDRVLYGRSYGWYFDV	6	hVK1-33	mJK2	QQYDNLPT	3
SP1-62	SPIKE-BC1-6-2	SP1		hVH1-2	mJH1	ARDRVLYGRSYGWYFDV	7	hVK1-33	mJK2	QQYDNLPT	4
SP1-73	SPIKE-BC1-7-3			hVH1-2	mJH1	ARDRVLYGRSYGWYFDV	2	hVK1-33	mJK2	QQYDNLPT	5
SP1-96	SPIKE-BC1-9-6			hVH1-2	mJH1	ARDRVLYGRSYGWYFDV	6	hVK1-33	mJK2	QQYDNLPT	2
SP2-16	SPIKE-BC2-1-6			hVH1-2	mJH4	ARERRVIHYSGILYALDY	7	hVK1-33	mJK2	QQYDNLHMFT	2
SP2-122	SPIKE-BC2-12-2	SP2		hVH1-2	mJH4	ARERRVIHYYGILYALDY	5	hVK1-33	mJK2	QQYDNLHMFT	1
SP2-125	SPIKE-BC2-12-5			hVH1-2	mJH4	ARERRVIHYSGILYALDY	3	hVK1-33	mJK2	QQYDNLHMFT	2
SP2-48	SPIKE-BC2-4-8			hVH1-2	mJH4	ARERRVIHYYGILYAMDY	3	hVK1-33	mJK2	QQYDDLHMFT	1
SP3-101	SPIKE-BC3-10-1		SARS-CoV2 spike	hVH1-2	mJH3	AITGRRPWFPF	11	hVK1-33	mJK2	QQYDNLPYT	7
SP3-42	SPIKE-BC3-4-2	SP3		hVH1-2	mJH3	AITGRRPWFPY	6	hVK1-33	mJK2	QQYDYLPYT	7
SP3-46	SPIKE-BC3-4-6			hVH1-2	mJH3	AITGRRPWFAN	8	hVK1-33	mJK2	QQYDYLPYT	6
SP3-98	SPIKE-BC3-9-8			hVH1-2	mJH3	TITGRRPFFPY	7	hVK1-33	mJK2	QQYDNLPYT	5
SP4-102	SPIKE-BC4-10-2			hVH1-2	mJH3	ARGERRSWFTY	10	hVK1-33	mJK2	QQYDNLPYT	10
SP4-113	SPIKE-BC4-11-3			hVH1-2	mJH3	ARGERRSWFTY	10	hVK1-33	mJK2	QQYDNLPYT	7
SP4-73	SPIKE-BC4-7-3			hVH1-2	mJH3	ARGERRSWFTY	10	hVK1-33	mJK2	QQYDNLPYT	5
SP4-15	SPIKE-BC4-1-5	SP4		hVH1-2	mJH3	ARGGRRTWFAY	9	hVK1-33	mJK2	QQYDYLPYT	4
SP4-65	SPIKE-BC4-6-5			hVH1-2	mJH3	ARGARRTWFAY	10	hVK1-33	mJK2	QQYDNLPYT	2
SP4-87	SPIKE-BC4-8-7			hVH1-2	mJH3	ARGGRRTWFAY	9	hVK1-33	mJK2	QQYDYLPYT	3
VHH7-3-37	VHH7-BC3-37	VHH7-3		hVH1-2	mJH3	ARDLGDYDAWFAY	0	hVK1-33	mJK1	QQYDNLRWT	6
VHH7-3-66	VHH7-BC3-66			hVH1-2	mJH3	ARDLGDYDAWFAY	0	hVK1-33	mJK1	QQYDNLRWT	3
VHH7-5-29	VHH7-BC5-29			hVH1-2	mJH3	ARDRVGQRFVY	9	hVK1-33	mJK1	QQYDNLWT	7
VHH7-5-75	VHH7-BC5-75	VHH7-5		hVH1-2	mJH3	ARDRVGQRFPY	9	hVK1-33	mJK1	QQYDYLWT	3
VHH7-5-82	VHH7-BC5-82			hVH1-2	mJH3	ARDRVGQRFPY	5	hVK1-33	mJK1	QQYDNLWT	4
VHH7-7-53	VHH7-BC7-53		VHH7-RBD (VHH7 nanobody target MHCII)	hVH1-2	mJH2	ARRNCDY	5	hVK1-33	mJK2	QQYDNLPYT	1
VHH7-7-76	VHH7-BC7-76	VHH7-7		hVH1-2	mJH2	ARRNCDY	4	hVK1-33	mJK2	QQYDNLPYT	1
VHH7-7-79	VHH7-BC7-79			hVH1-2	mJH2	ARRNCDY	4	hVK1-33	mJK2	QQYDNLPYT	3
VHH7-7-85	VHH7-BC7-85			hVH1-2	mJH2	ARRNCDN	4	hVK1-33	mJK2	QQYDNLPYT	3
VHH7-8-5	VHH7-BC8-5			hVH1-2	mJH3	ARGRGGTSWLAY	6	hVK1-33	mJK2	QQYDNLYT	3
VHH7-8-59	VHH7-BC8-59	VHH7-8		hVH1-2	mJH3	ARGKGGTSWFAY	3	hVK1-33	mJK2	QQYDNLCT	1
VHH7-8-62	VHH7-BC8-62			hVH1-2	mJH3	ARGKGGTSWFAY	3	hVK1-33	mJK2	QQYDNLYT	1
VHH7-8-7	VHH7-BC8-7			hVH1-2	mJH3	ARGRGGTSWFAY	4	hVK1-33	mJK2	QQYDNLYT	1
VHH7-10-19	VHH7-BC10-19	VHH7-10		hVH1-2	mJH2	ARDPLTGIFDY	6	hVK1-33	mJK2	QQYDNLPYMYT	1

Table S3: Cryo-EM statistics.

	Full-length SARS-CoV-2 G614 S:P1-37 Fab		RBD:P1-37 Fab
Data collection and processing			
Microscope	Titan Krios		Titan Krios
Voltage(kV)	300		300
Detector	Gatan K3		Gatan K3
Magnification(nominal)	105,000		105,000
Energy filter slit width (eV)	20		20
Calibrated pixel size (Å/pix)	0.83		0.83
Exposure rate (e$^-$/pix/sec)	13.761		13.761
Frames per exposure	50		50
Total electron exposure (e$^-$/Å^2)	53.853		53.853
Exposure per frame (e$^-$/Å^2)	1.077		1.077
Defocus range (μm)	-0.5,-2.2		-0.5,-2.2
Automation software	SerialEM		SerialEM
# of Micrographs used	34,031		34,031
Particles extracted	7,657,522		7,657,522
Particles after 2D classification	3,849,421		3,849,421
Class	RBD-down	RBD-up	RBD-down
Total # of refined particles	250,319	209,249	250,319
Symmetry imposed	C3	C1	C1
Map resolution (Å)	2.7	2.9	3.2
FSC threshold	0.143	0.143	0.143
Map sharpening B factor (Å^2)	-88.3	-75.8	-101.5
Refinement			
Initial model used (PDB ID)	7KRQ, 6WS6,AlphaFold	7KRR, 6WS6,AlphaFold	6WS6, AlphaFold
Model composition			
Non-hydrogen atoms			
Amino acids	4674	4619	635
Glycans	54	57	1
RMSD bonds (Å)	0.014	0.013	0.012
RMSD angles (∘)	1.86	1.84	1.87
Mean B-factors			
Amino acids	41	66	71
Glycans	56	94	86
Ramachandran			
Favored (%)	93.04	93.36	93.16
Allowed(%)	5.86	5.70	5.41
Outliers(%)	1.10	0.94	1.43
Rotamer outliers (%)	2.59	2.22	2.20
Clash score	4.66	5.04	5.28
C-beta outliers (%)	0.53	0.39	0.68
CaBLAM outliers (%)	2.63	2.43	2.41
CC (mask)	0.79	0.77	0.87
CC (volume)	0.74	0.74	0.85
MolProbity score	2.00	1.96	1.98
EMRinger score	4.29	3.76	3.81

Table S4: sgRNA sequences for genome editing and primer sequences for single cell RT-PCR.

Method	Name	Sequence	Scourse
sgRNAs	mVH-deletion-px459-sgRNA1	TTAGCAACAGCTGCACGTAA	Dai et.al, 2020
	mVH-deletion-px459-sgRNA2	TGGTTGTTAGGACATGCCTA	Dai et.al, 2020
	mVK3-2 sgRNA1	AGAGAAGCAGGACCCATAGC	This paper
	mVK3-2 sgRNA2	GTATTTCTGTCAGCAAAGTA	This paper
	mVK3-7 sgRNA	AGCTAGATGTACTGACACTT	This paper
	Cer/sis deletion-sgRNA1	GCAGAGATCTCAATTTGGCC	This paper
	Cer/sis deletion-sgRNA2	GAGGAATCTATGTCCTGGAT	This paper
single Cell RT-PCR	Cmu RT primer	ACCTTCAAGGATGCTCTTGG	Tian et al, 2016
	Cg1 and Cg2a RT primer	CAGCTGGGAAGGTGTGCACA	Tian et al, 2016
	CK RT primer	GCCTCACAGGTATAGCTGTT	Tian et al, 2016
	Cmu outer-R	CCTGGATGACTTCAGTGTTG	Tian et al, 2016
	Cg1 and Cg2a ouTer-R	AGGGATCCAGAGTTCCAGGT	Tian et al, 2016
	CK outer-R	GGACGCCATTTTGTCGTTCA	Tian et al, 2016
	Cmu inner-R	AGGGGGAAGACATTTGGGAAGGAC	Tian et al, 2016
	Cg1 inner-R	GCTCAGGGAAATAGCCCTTGAC	Tian et al, 2016
	Cg2a inner-R	ACTCAGGGAAGTAGCCCTTGAC	Tian et al, 2016
	CK inner-R	CTTGACATTGATGTCTTTGGGGTAG	This paper
	VH1-2 primer-F	TGGACCTGGAGGATCCTCTT	Tian et al, 2016
	VK3-20 primer-F	TTCCTCCTGCTACTCTGGCT	Tian et al, 2016
	VK1-33 primer-F	TCAGCTCCTGGGGCTCCTGC	This paper